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I am among those who think that science has great beauty. A scientist in his laboratory is 
not only a technician: he is also a child placed before natural phenomena which impress 
him like a fairy tale. 
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Nuclear receptors are ligand-activated transcription factors, where upon binding 
with small molecule ligands, these proteins are involved in the regulation of gene 
expression. To date there are approximately 48 human nuclear receptors known, involved 
in multiple biological and cellular processes, ranging from differentiation to maintenance 
of homeostasis.  Due to their critical role in transcriptional regulation, these receptors are 
implicated in several diseases. Currently, 13% of prescribed drugs in the market are NR 
ligands for diseases such as cancer, diabetes and osteoporosis. Issues such as drug 
resistance, as seen with the highly successful breast cancer therapeutic drug, tamoxifen, 
present a critical need for the continuous identification of novel small molecules that can 
serve as potential ligands for these receptors, developing new drugs. In addition to drug 
discovery, the mechanism of function, mobility and trafficking of these receptors is 
poorly understood.  Gaining insight into the relationship between the function and /or 
dysfunction of these receptors and their mobility will aid in a better understanding of the 
role of these receptors.   
The green fluorescent protein (GFP) has revolutionized molecular biology by 
providing the ability to monitor protein function and structure via fluorescence.  The 
fluorescence from this biological marker arises from the chromophore, formed from the 
polypeptide backbone of three amino acid residues, buried inside 11-stranded β-barrel 
protein. Synthesis of GFP derivatives is based on the structure of the 
arylmethyleneimidazolidinone (AMI), creating a molecule that is only weakly 
fluorescent. Certain AMI derivatives have previously been designed to bind the human
 
 xxii 
serum albumin (HSA) protein, showing fluorescence upon protein binding.  
Characterizing these AMI derivatives for other proteins can provide a powerful 
visualization tool for analysis of protein function and structure. This development could 
provide a very powerful method for protein analysis in vitro and in vivo.  
Development of such fluorescent ligands will prove beneficial for the nuclear 
receptors. Current methods for visualizing these receptors involve creating fusion 
proteins with the green fluorescent protein (GFP).  Nuclear receptors are involved in 
multiple cascades of protein/protein interactions, and the presence of a bulky 
fluorescence protein might prevent the natural function of the receptor by eliminating the 
surface area needed for critical protein/protein contacts.  Therefore, the development of 
fluorogens links the fluorescence to a small molecule ligand, more natural to the function 
of the receptor, serving as the tool needed for visualization and the trafficking of these 
receptors in vivo. 
In this work, libraries of AMIs derivatives were synthesized by manipulating 
various R groups around the core structure, and tested for their ability to serve as nuclear 
receptor ligands with the ability to fluoresce upon binding. The fluorogens are developed 
for steroidal and non-steroidal receptors, two general classes of nuclear receptors.  
Specific AMIs were designed and developed for steroid receptor estrogen receptor α 
(ERα). These ligands are showed to activate the receptor with an EC50 value of 3 µM and 
the 10-fold activation with AMI 1 and AMI 2 in comparison to the 21-fold activation 
observed with natural ERα ligand, 17β-estradiol. These novel ligands were not able to 
display the fluorescence upon binding the receptor.  However, fluorescence localized in 
nucleus was observed in the case of another AMI derivative, AMI 10, which does not 
 
 xxiii 
activate the receptor. Such ligands open new avenues for developing fluorescent probes 
for ERα that do not involve fluorescent conjugates attached to a known ERα ligand core. 
AMIs were also characterized for non-steroidal receptors, specifically the 
pregnane x receptor (PXR) and retinoic acid receptor α (RARα). To date, fluorogens 
which turn fluorescence upon binding and activate the receptor have not been developed 
for these receptors. With respect to PXR, several AMI derivatives were discovered to 
bind and activate this receptor with a fold-activation better than the known agonist, 
rifampicin.  The best characterized AMI derivative, AMI 4, activates the receptor with an 
EC50 of value 6.3 µM and the 154-fold activation in comparison to the 90-fold activation 
and an EC50 value of 1.3 µM seen with rifamipicin. This ligand is not only able to 
activate PXR but also displays fluorescence upon binding to the receptor. The 
fluorescence pattern was observed around the nucleus.   Besides AMI 4, 16 other AMI 
derivatives are identified that activate PXR with different activation profiles. Thus, a 
novel class of PXR ligands with fluorescence ability has been developed.  
The AMI derivatives able to bind and activate RAR, also displayed activation profiles 
that were comparable to the wild-type ligand, all trans retinoic acid.  These ligands 
activated the receptor with an EC50 value of 220 nM for AMI 109 in comparison to an 
EC50 value of 0.8 nM with the natural ligand for RARα. When these ligands were tested 
for fluorescence in yeast, the yeast were able to fluoresce only in the presence of the 
receptor and the AMI derivative, indicating that these agonists also have the ability to 
fluoresce.   
To provide the opportunity to gain further insight into interaction between the 
ligand and the receptor, these nuclear receptors were also subjected to rounds of 
 
 xxiv 
mutagenesis, engineering receptors with the ability to bind AMI derivatives.  The most 
promising of these rounds of mutagenesis was the discovery of an estrogen receptor α 
variant, E380D that showed an increase in the fold activation from two fold to five fold 
with AMI 2 in comparison to the wild-type receptor. This variant also showed an 
enhanced fluorescence with AMI 1 and 2 in comparison to the wild-type receptor. 
Interestingly, the variants have mutations outside of the ligand binding pocket, showing 
the importance of residues that are not in direct contact with the ligand and how the 
secondary shell residues and even those on the surface of the protein could have an 
allosteric effect on ligand binding. 
The discovery of this novel class of ligands, AMIs, for various nuclear receptors 
indicates that they can serve as strong candidates for these receptors, in terms of drug 
development and resources for visualizing nuclear receptor mobility and trafficking. 
These fluorogens hold great promise as perhaps the next generation of novel ligands for 
various nuclear receptors and will perhaps allow a better understanding of the 










1.1 Nuclear Receptor Superfamily 
 The control of gene expression is essential for development, metabolism and cell 
function. Nuclear receptors are a large family of ligand dependent transcription factors 
that regulate gene transcription. They play crucial roles in a number of important 
biological and physiological processes [1-3].  Hormones, endogenous small molecules, 
act as ligands to the nuclear receptors to control expression of specific genes [4].  
 Due to their essential functions, nuclear receptors are present even in the simplest 
of the organisms, and first appeared around 635 million years ago [5]. However, it is 
hypothesized that the original nuclear receptors were primarily environmental sensors 
due to the lack of endocrine organs present at that time in the simple life form [1, 6, 7]. 
The development of the complex endocrine system in evolution of bilateral animals 
caused the nuclear receptors to evolve in binding various hormones, thus serving as 
transcription factors. To date, 900 nuclear receptor genes have been identified in every 
species[5].  Mammals, including humans, have 48 nuclear receptors [8, 9].  While about 
half of these receptors have ligands that have been identified, several others do not have a 
known “natural” ligand associated with them and are called “orphan nuclear receptors”. 
However, in such cases several metabolic intermediates have been identified as potential 
ligands [10, 11].  A few nuclear receptors, such as Nurr1 and HR38, do not possess the 
typical binding pocket, as their pocket is filled with the side chain amino acids, serving as 
constitutively active receptors[12, 13].  
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 The majority of nuclear receptors bind a variety of small, hydrophobic molecules 
that are derivatives of fatty acids, retinoids, vitamins and hormones. Based on the types 
of small molecules these receptors bind, the superfamily of nuclear receptors is divided 
into subfamilies [8, 14]. Thus, estrogen receptor (ERα-β), estrogen related receptor 
(ERRα-γ), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone 
receptor (PR) and androgen receptor (AR) belong to the steroid family of nuclear 
receptors as they bind to the derivatives of the steroids[15]. Other nuclear receptors are 
activated by retinoids or fatty acids, such as retinoid x receptor and peroxisome 
proliferator activated receptor (PPARγ), therefore creating the non-steroidal 
subfamily[16] [17, 18]. The pregnane x receptor (PXR) is the example of an orphan 
nuclear receptor, due to the lack of an identified natural ligand for it but is found to be 
activated by various xenobiotic ligands [19, 20]. The wide diversity of ligands that  bind 
and activate the nuclear receptors in nanomolar affinity and with high specificity, allow 
these receptors to perform their specific functions, such as controlling embryonic 
development and homeostatis [21].  Due to their critical role in transcriptional regulation, 
these receptors are implicated in several diseases. Hence, there is a vast interest in 
discovering ligands for these receptors as potential therapeutic drugs [22].  Currently, 
13% of prescribed drugs in the market  (e.g. Advair, Avandia and Faslodex) are NR 
ligands for diseases such as  cancer, diabetes and osteoporosis[5, 23], while the  nuclear 
receptor ligands such as dibenzodiazepine derivatives have recently been developed for 
schizophrenia, autism and  Parkinson’s disease [24, 25]. However, the issues such as drug 
resistance and toxicity indicate that there is a critical need for the identification of a novel 
class of small molecules as potential ligands for such nuclear receptors.   
 3 
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Figure 1.1 Scheme of nuclear receptors structure. The visual 
structure of DBD (yellow) and LBD (pink). 
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1.2 Structure of Nuclear Receptors 
 Nuclear receptors share a common structural organization, which includes five 
main domains: the N- terminal A/B domain containing transcriptional activation function 
1 domain (AF-1), the C domain known as the central DNA binding domain (DBD), a 
flexible hinge D region and the E domain containing the carboxy terminal ligand binding 
domain (LBD) with the activation function 2 domain (AF-2) (Figure 1.1) [14, 26, 27]. 
 Nuclear receptors contain two transcriptional activation domains which interact 
with co-regulatory proteins. The AF-1 domain is the least conserved domain among the 
nuclear receptor domains, significantly varying in length and sequence composition. This 
trans-activational domain is also thought to be intrinsically disordered (ID), making the 
analysis of the structure - function relationship difficult [ 28,29]. More recently, it has 
been discovered that this domain is able to interact with many co-regulatory proteins 
[30].  Even though this domain acts as ligand independent transcriptional activator, it 
synergizes its action with AF-2 domain, which is responsible for interactions with the co-
activators. 
 The DNA binding domain (DBD) is the most conserved structural domain within 
the nuclear receptor superfamily. In case of the DBD, structural data has been reported 
for many nuclear receptors, and has been shown to consist of helices interacting with the 
major groove and specific bases, while the second helix stabilizes the domain (Figure 
1.2). The crucial role in binding DBD is played by  two zinc finger motifs that  are 
created from two zinc ions which are coordinated by four cysteine residues [1, 15, 26, 
31]. All nuclear receptors interact with a specific DNA sequence called response  
 5 
 
Figure 1.2 Structure of DNA binding domain. DNA binding 
domain as heterodimer (green and blue), response elements (orange) 
and Zn (II) ions (red). PDB:1DSZ 
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elements (RE). Response elements are located relatively close to the gene of interest that 
is activated by nuclear receptor. They are created from direct or indirect (palindromic) 
repeats of specific sequence 5’-AGAACA-3’ or 5’-AGGTCA-3’, that are separated by 
few nucleotides[1]. 
 Nuclear receptors can be subdivided into three groups based on the way they bind 
to the response elements: steroids receptors such as ER and GR that  bind to DNA as 
homodimers, receptors that can interact with response elements as heterodimers (e.g. 
VDR, LXR and RAR) and nuclear receptors that bind as monomers (e.g. steroidogenic 
receptor (SF-1) and ERR) . 
 The DBD is connected to the ligand binding domain (LBD) via a hinge region. 
However, recent studies have indicated that the hinge region is not only the flexible 
linker that allows for correct DNA binding and dimerization but also a part of it, which 
includes about 12 residues called a carboxy terminal extension (CTE), that directly 
participates in binding to the DNA [32, 33]. This region is not conserved among all the 
nuclear receptors and creates significantly different structural motifs. Thus, the CTE of 
thyroid hormone receptor (TR) creates a helix that interacts with the DNA along with the 
other two helices that  are part of the DBD [34]. 
 The LBD is the most characterized domain of nuclear receptors. Extensive 
structural studies have revealed a great amount of information about the structure - 
function relationship of this domain. The LBD of the most nuclear receptors consists of a 
canonical fold containing about 10-13  helices, two to five β strands, and the variable 
loops, which are arranged into an anti-parallel, three-layered sandwich (Figure 1.3)[35]. 
 7 
A B 
Figure 1.3 Structure of the ligand binding domain. A and B LBD shown 
from different side. Helix 12 is shown in red, ligand (purple). PDB: 4LBD 
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  The LBD’s primary role is the binding of a small molecule ligand, in its ligand 
binding pocket (LBP). The LBP is formed from helices 3, 7, 10 and β-turn, creating a  
predominantly hydrophobic pocket. However, several polar residues are responsible for 
the crucial interactions with the ligand[9]. Due to a wide range of ligands that bind and 
activate nuclear receptors, the size and shape of LBP varies depending on the type of 
nuclear receptor, ranging from 400 Å3 observed with ERα to 1600 Å3, observed with 
PXR[8, 36].  
 The role of helix 12 of the LBD is crucial in these receptors. Upon ligand binding, 
helix 12 changes its conformation, from a freely mobile structure in solvent to a more 
stabilized conformation, moving to the surface of the protein (Figure 1.4) [37].  A part of 
this helix is the ligand regulated transcriptional activation function domain (AF-2), which 
is responsible for allosteric interaction with co-regulators. In the absence of the ligand 
(apo) or in the presence of an antagonist, the LBD interacts with the nuclear receptor 
corepressor such as NCoR1 and SMRT [38, 39]. However, agonist binding leads to a 
conformational change of helix 12, positioning the AF2 domain in the orientation for co-
activator binding. Conformational flexibility of helix 12 is crucial for creating 
transcriptional response based on the antagonist or the agonist binding [18]. 
 Crystal structures solved for many DBDs and LBDs revealed several structural 
details about the function of the nuclear receptor domains. However, domain-domain 
interactions were not well defined due to the lack of various full length ligand-bearing 
nuclear receptors. To date, there is only one full length crystal structure of a nuclear 
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receptor that  includes LBD and DBD of PPARγ as a heterodimer with RXRα, bound to 
DNA and the co-activator peptides (Figure 1.5)[40].  
Figure 1.4 Ligand binding induces conformational change of the LBD of 














































1.3 Function of Nuclear Receptors 
 Each of the 48 members of the human nuclear receptor family is able to turn on 
the transcription of various genes by binding to specific response elements. Without 
ligand, the nuclear receptor interacts with corepressor, such as nuclear receptor 
corepressor 1 (NCoR1) or silencing mediator for retinoid and thyroid hormone receptor 
(NCoR2, SMRT). These proteins bind to hydrophobic grooves created between helices 3 
and 4, forming a corepressor nuclear receptor box [41]. Corepressor proteins in turn 
recruit histone deacetylases (HDAC), which are responsible for condensation of 
chromatin above the gene promoter and the repressor of gene transcription [42]. When 
the agonist binds to the nuclear receptor, helix 12 undergoes a conformational change that 
leads to corepressor dissociation and creation of coactivator binding site. Coactivators, 
such as the steroid receptor coactivator 1 (SRC-1) and the activator for thyroid and 
retinoid receptors (ACTR) interact with LBD through LXXLL NR box, where L is 
leucine and X is any amino acid [43, 44]. Coactivators create complexes with histone 
acetyltransferase (HAT), which acetylate the lysine residues on the histones, thus 
weakening the interactions between the DNA and the histones. This in turn allows for the 
recruitment of the RNA polymerase and initiates the transcription (Figure 1.6) [45]. 
 Next to coactivator and corepressor site, the nuclear receptor function is also 
modulated by the other protein–protein interaction by binding function–3 (BF-3). This 
recently found site brings a new site for the allosteric control of nuclear receptors [46, 
47]. This site is highly conserved among the nuclear receptors and the mutations in this 
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Figure 1.6 Transcriptional regulations by nuclear receptors. 
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and other diseases. Unfortunately, the binder protein has not been found to bind the 
surface of the BF-3 site [48].  
 These recent findings indicate that allosteric modulation of the nuclear receptor is 
essential for the proper function of the nuclear receptors and more work needs to be done 
to understand how this interaction directly and indirectly influences the transcription 
activation. Such knowledge would play a significant role in the development of the novel 
transcription modulators. 
   
1.4 Diversity of Nuclear Receptor Ligands 
 
 Transcriptional regulation by nuclear receptors via binding small molecule 
ligands opens avenues for the development of various drugs for nuclear receptor related 
diseases, such as cancer and diabetes. Most of the synthetic ligands are based on natural 
ligands that bind and active NRs. Nuclear receptor ligands are mainly hydrophobic, small 
molecules, with structural diversity and also include retinoids and antibiotics (Figure 1.7). 
They also vary in size from 220 to 1600 angstrom [6, 49, 50]. However, the mean volume 
of endogenous ligands is 318 Å3 (SD: 53 Å3) and is conserved across nuclear 
receptors[50]. Interestingly, the ligands for nuclear receptors are evolved from the 
biomarkers for early microorganisms. For instance, okenane which is a derivative of 
carotenoid, the precursor to retinoic acid, was extracted from sedimentary rocks 1600 
million years ago[51]. Thus, nuclear receptor ligands have origins much older than the 
nuclear receptors themselves. The high diversity of ligands allows for strong selectivity 
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Figure 1.7 Structure of nuclear receptor ligands. 
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are able to give transcriptional response in nanomolar ligand concentration, but fatty 
acids need 100,000 times higher concentration than steroids to active PPARγ [5].  Thus,   
the receptor response is related to the concentration of these ligands in the human body. 
 Such diversity in shape, size and sensitivity has influence on the kind of response 
that ligands induce towards nuclear receptors. Based on the kind of transcriptional 
response, a few classes of ligands can be identified:  agonists, inverse agonist, antagonist, 
partial antagonists, selective nuclear receptor modulators (SERMs) and selective nuclear 
receptors downregulators (SERDs) [52-54]. These ligand classes differ in influence on 
the position of the helix 12 and in creating interface with corepressor or coactivators. 
Understanding the correlation between the ligand structure and its effects on the 
transcriptional activity is crucial for creating the novel ligands that will induce the 
specific physiological response. 
 
1.5 Detection of trafficking of nuclear receptors 
 
 Nuclear receptors are predominantly located in the nucleus, due to their ability to 
bind to the specific DNA sites and response elements and to modulate transcriptional 
response. However, some of nuclear receptors such as ER and GR are located in the 
nucleus as well as in the cytosol. In the cytoplasm they are complexed with the heat 
shock protein (HSP) and with the corepressors. As soon as the proper ligand binds the 
nuclear receptor, the HSP dissociates and the nuclear receptor is translocated from 
cytoplasm to the nucleus, where coactivator binding allows for the interaction of NR with 
the response elements and turns on the transcription of the specific gene [55]. Recent 
finding shows that some nuclear receptors such PPAR are shuttled between the nucleus 
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and the cytoplasm. This creates questions about trafficking and function of the nuclear 
receptors outside of the nucleus, especially that many NRs have been found in the 
membranes and in cellular organelles such us mitochondria [56, 57].  
 Thus, the nuclear receptor trafficking in the cell has been the subject of studies to 
understand the mobility of different subfamilies of NR between the cell compartments. 
To observe trafficking, nuclear receptors in the cell fluorescent marker have been used in 
previous studies. The most common method is the fusion of green fluorescent protein 
(GFP) to the nuclear receptor. Previously, this method has been reported successfully to 
visualize the NR in the cell [58, 59]. However, the bulky GFP protein could be 
responsible for disrupting interaction of nuclear receptor with coregulatory protein such 
as coactivators. Therefore, it can influence the mobility of NR in the cell and may not 
present the actual state of this receptor in vivo.  
 The nuclear receptor can also be visualized using the radiolabeled ligands. 
Previously, using this method, localization of ERα and TR has been reported [60, 61]. 
Due to the restrictions on using the radiolabeled compounds as a biosensor, the 
development of the fluorescent ligand has progressed.  Recently NR ligands conjugated 
with fluorescent dye have been made to allow for the visualization of NRs in vivo. 
However, these conjugated ligands have shown significantly lower binding affinities [62-
64].  
 These recent findings suggest that the development of novel fluorescent ligands is 
needed to study the nuclear receptor trafficking and to reveal the expression patterns in 
specific tissues. Such ligands will also aid in gaining detailed understanding of the 
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GREEN FLUORESCENT CHROMOPHORES 
 
2.1 Green Fluorescent Protein (GFP) 
 The green fluorescent protein (GFP) discovered in 1962 in the jellyfish Auquorea 
victoria is the most well known molecular imaging tool used in chemistry, biology and 
medicine [1]. However, 30 years after discovery of GFP, first cloning and in vivo 
expression of GFP (fluorescence displayed in bacteria and C. elegans) demonstrated that 
this protein can be used as a marker of gene expression and trafficking of protein in the 
cell [2, 3]. This finding made GFP one of the most powerful molecular biology tools. 
Now, GFP is being used as a fluorescent tag that can be fused to N or C terminal part of 
many proteins without disturbing their native functions (in most of the cases) [4, 5]. It has 
been shown to be successfully expressed in bacteria, yeast, zebrafish, plants and 
mammalian cells [6-8]. 
 To date, there are over 200 solved crystal structures of GFP and GFP-like proteins 
which are fluorescent proteins from other marine organisms and numerous GFP mutants 
[9]. This large amount of data gave insight into structures and properties of GFP. GFP is 
composed of 238 residues and is folded into the 11-stranded β-barrel structure with single 
α helix that is positioned in the center of the barrel (Figure 2.1)[10]. These 11 strands of 
the sheet create almost symmetrical structure. Thus, the β-barrel constructed seems to 
create a protective environment for the chromophore which is positioned in the center of 
the barrel. The chromophore, 4-(p-hydroxybenzylidene)-5-imidazolinone (p-HBI) is 
formed by an autocatalytic, posttranslational cyclization and oxidation of the polypeptide 
 24 
Figure 2.1 Structure of Green Fluorescent Protein (GFP). 
 25 
 backbone, involving Ser-65, Tyr-66 and Gly-67 residues (Figure 2.2) [11]. 
Chromophore, the component of GFP, which is responsible for the green fluorescence is 
protected from the solvent by short helices. However, several water molecules have been 
found also inside the barrel. They are responsible for creating hydrogen bonding network 
around chromophore which together with other amino acid side chains and hydrophobic 
contacts is crucial for photochemical properties of GFP [4]. This tightly constructed 
hydrogen bond network keeps the conjugated rings of chromophore in almost co-planar 
orientation and does not allow the rings to twist. Chromophore’s cis-configuration is 
mainly responsible for the fluorescence of GFP [2].  
The wild-type GFP chromophore exhibits two absorption peaks at 398 nm and 
477 nm corresponding to the neutral form and the anionic form [12, 13]. The emission 
peak is at 508 nm. Photochemical properties of GFP change upon denaturation, GFP 
exhibits absorption maxima at 370 nm and an emission peak at 440 nm with loss of 
fluorescence quantum yield [12]. Photochemical properties of the protein can also be 
modified by point mutations. Many mutagenesis studies of GFP have shown that point 
mutations can change spectral response of chromophore [14, 15]. The change in position 
65 from threonine to serine S65T creates GFP variant (eGFP) with enhanced fluorescence 
with absorption at a single peak of 484 nm and an emission maximum at 507.  
Change of the protein microenvironment by introducing specific mutations not 
only creates enhanced fluorescence of GFP but also can create many fluorescent protein 
(FP) color variants. Thus, mostly random mutagenesis studies have developed different 
FP variants with wide range of emission spectra (Figure 2.3). Fluorescent proteins are 









































































Figure 2.3 Variety of fluorescent proteins exhibiting different spectroscopic properties 
with their respective chromophores. 
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BFP with emission spectrum 440–470 nm, cyan CFP (471–500 nm), yellow YFP (521–
550 nm), orange OFP (551–575 nm) and red RFP (576–610 nm) [16]. To receive 
significant change in emission spectrum, the core of chromophore has to be changed by 
mutagenesis. For instance, in case of BFP, replacement of the tyrosine at position 66 by 
histidine results in blue shifted emission spectrum, but also causes low fluorescence 
quantum yield [11]. 
The GFP and its variants’ unique properties have revolutionized the study of cell 
biology. The number of applications of GFP as a fluorescent probe is growing 
continuously and brings opportunity to monitor the gene expression, as well as, to study 
function and localization of many proteins in the cell. However, GFP also has a 
limitation. GFP fused to the protein does not interact with the natural function of this 
protein in most of the cases. Some proteins, such as nuclear receptors change 
conformation upon binding and interact with many regulatory proteins. Thus, a bulky 
GFP can interfere with the protein and can disrupt the function of the nuclear receptors.  
 
2.2 Synthesis of Arylmethyleneimidazolodinone (AMI) 
 The derivatives of chromophore have been designed based on 
arylmethyleneimidazolidinone (AMI).  Based on the AMI core structure, a variety of 
chromophore analogs have been designed, to activate specific nuclear receptors, 
providing chromophore emission upon binding to the receptor’s ligand binding domain 
(LBD). To achieve specificity of AMIs for particular nuclear receptors, side chains of the 
core of AMIs (R1 and R2) have been modified to incorporate various molecular 
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interactions, such as hydrogen bonding and hydrophobic contacts with the various 
residues in the ligand binding pocket. 
  Such a large number of AMI derivatives needed not only a quick and reliable 
synthesis method but also a method that will allow one to synthesize a variety of 
substituted imidazolinones which can provide efficiency, directness and a diversity of 
functional groups. Thus, the method developed by Dr. Anthony Baldridge (PhD., Georgia 
Tech, 2011) was based on the adaptation of methodology proposed previously by 
Bazureau and Grigg. 
Synthesis of AMIs is carried out with three step synthesis (Figure 2.4) [17]. The first part 
of the synthesis requires production of iminoglycine methyl ester. It is produced from the 
reaction of ethyl acetimidate hydrochloride with glycine methyl ester hydrochloride. 
Next, the synthesis of 4-arylideneimidazolin-5-one, the Schiff base, is required. It is 
synthesized in high yields by condensation of aromatic an aldehydes and a primary 
amines. This step is significant for the development of AMI derivatives due to functional 
groups that are carried on both aromatic aldehydes and aliphatic amines. Both of these 
compounds are commercially available and bring opportunity to generate a variety of 
AMIs in a fast manner. The last part of the synthesis is 2+3 cycloaddition, which leads to 
creation of arylideneimidazolinones. In this reaction, the Schiff base provides the 
aromatic substituent, as well as the amide nitrogen of the imidazolinone, while the other 





Figure 2.4 Synthetic scheme of the 2+3 cycloaddition. 
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2.3 Arylmethyleneimidazolidinone (AMI) Chromophore for various Proteins 
  The AMIs, synthetic compounds derived from the imidazolidinone chromophore 
of the green fluorescent protein (GFP) from Aequorea victoria are known to be weakly 
fluorescent [4]. The derivatives of AMI developed did not display enhanced fluorescence 
in the solution. The weak fluorescence is due to vibrational modes of the unbound 
chromophore. Previously, it has been stated that the high fluorescence of GFP 
chromophore is a result of the cis configuration and co-planar orientation of molecule 
inside the β-barrel [2]. Lack of the protein host increases conformational freedom of 
chromophore and results in the weak fluorescence. Thus, replacing the β-barrel with 
another host protein could increase the fluorescence quantum yield of synthesized AMI. 
Mimicking the β-barrel by binding the chromophore to the protein could restore 
fluorescence and open new avenues for synthesized AMIs to provide a very powerful 
method for protein analysis in vitro and in vivo. Previously, it has been reported that 
several AMIs are able to bind to human serum albumin (HSA) and enhanced the emission 
quantum yield significantly [18]. HSA is a blood plasma protein and is able to bind many 
different ligands due to its 12 ligand binding pockets. The group of ligands with long 
alkyl chain displays a significantly higher fluorescence quantum yield in comparison to 
the other members of the library of AMI derivatives. There is visibly clear correlation 
between length of the aliphatic chain and the fluorescence. The highest fluorescence 
quantum yield was displayed in case of hexyl and heptyl chain in comparison to the 
shorter alkyl chains. These results suggested that increasing hydrophobicity by 
incorporation of longer alkyl chain results in higher fluorescence level. The hydrophobic 
pocket of HSA creates a similar environment for AMI that the β-barrel created for the 
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chromophore. These findings are promising for the other proteins as well. Design and 
synthesis of AMI derivatives that can specifically bind to the chosen protein brings an 
opportunity to create fluorescent ligands for various proteins. These ligands differ from 
other known fluorescent molecules that display fluorescence only upon binding. Thus, 
they can be used as potential fluorescent probes for studying the mobility and trafficking 




1. Morin, J.G. and J.W. Hastings, Energy transfer in a bioluminescent system. J Cell 
Physiol, 1971. 77(3): p. 313-8. 
2. Sample, V., R.H. Newman, and J. Zhang, The structure and function of 
fluorescent proteins. Chem Soc Rev, 2009. 38(10): p. 2852-64. 
3. Prasher, D.C., et al., Primary structure of the Aequorea victoria green-fluorescent 
protein. Gene, 1992. 111(2): p. 229-33. 
4. Zimmer, M., Green fluorescent protein (GFP): applications, structure, and 
related photophysical behavior. Chem Rev, 2002. 102(3): p. 759-81. 
5. De Giorgi, F., et al., Targeting aequorin and green fluorescent protein to 
intracellular organelles. Gene, 1996. 173(1 Spec No): p. 113-7. 
6. Chalfie, M., et al., Green fluorescent protein as a marker for gene expression. 
Science, 1994. 263(5148): p. 802-5. 
7. Kahana, J.A., B.J. Schnapp, and P.A. Silver, Kinetics of spindle pole body 
separation in budding yeast. Proc Natl Acad Sci U S A, 1995. 92(21): p. 9707-11. 
 33 
8. Wang, S. and T. Hazelrigg, Implications for bcd mRNA localization from spatial 
distribution of exu protein in Drosophila oogenesis. Nature, 1994. 369(6479): p. 
400-03. 
9. Ong, W.J., et al., Function and structure of GFP-like proteins in the protein data 
bank. Mol Biosyst, 2011. 7(4): p. 984-92. 
10. Yang, F., L.G. Moss, and G.N. Phillips, Jr., The molecular structure of green 
fluorescent protein. Nat Biotechnol, 1996. 14(10): p. 1246-51. 
11. Tsien, R.Y., The green fluorescent protein. Annu Rev Biochem, 1998. 67: p. 509-
44. 
12. Bell, A.F., et al., Probing the ground state structure of the green fluorescent 
protein chromophore using Raman spectroscopy. Biochemistry, 2000. 39(15): p. 
4423-31. 
13. Rajput, J., et al., Photoabsorption studies of neutral green fluorescent protein 
model chromophores in vacuo. Phys Chem Chem Phys, 2009. 11(43): p. 9996-
10002. 
14. Brejc, K., et al., Structural basis for dual excitation and photoisomerization of the 
Aequorea victoria green fluorescent protein. Proc Natl Acad Sci U S A, 1997. 
94(6): p. 2306-11. 
15. Jung, G., J. Wiehler, and A. Zumbusch, The photophysics of green fluorescent 
protein: influence of the key amino acids at positions 65, 203, and 222. Biophys J, 
2005. 88(3): p. 1932-47. 
16. Pakhomov, A.A. and V.I. Martynov, GFP family: structural insights into spectral 
tuning. Chem Biol, 2008. 15(8): p. 755-64. 
17. Baldridge, A., et al., Activation of fluorescent protein chromophores by 
encapsulation. J Am Chem Soc, 2010. 132(5): p. 1498-9. 
18. Baldridge, A., et al., Recapture of GFP chromophore fluorescence in a protein 




FLUOROPHORES AS LIGANDS FOR THE HUMAN ESTROGEN 
RECEPTOR ALPHA 
  
3.1 Human Estrogen Receptor alpha 
 The estrogen receptor (ER) is a member of the NR superfamily and was among 
the first  NRs identified [1]. Estrogen receptors which include two main subtypes, ERα 
and ERβ, play crucial roles in human body, such as differentiation and proliferation. The 
wide distribution of ERs in various human tissues, including bone, uterus, breast and 
brain, along with their significant role in gene expression, implicates this receptor in a 
number of diseases, including breast cancer, osteoporosis, cardiovascular diseases, 
multiple sclerosis and Alzheimer’s disease [2-8]. Despite their similarity, both isotypes, 
ERα and ERβ, have different tissue distributions, ERα is prominently present in breast 
and uterus and ERβ is expresses highly in the prostate, salivary glands, testis, ovary and 
smooth muscles. 
 Endogenous estrogens, i.e., 17β-estradiol and its derivatives, are natural ligands 
for both isotypes [9]. 17 β-estradiol (E2) has higher affinity to ERα than ERβ (EC50 0.018 
and 0.039 nM, respectively) but ERβ is activated preferentially by phytoestrogens such as 
Genestein [10]. The differences in ligand preferences are in part due to different tissue 
distributions, but are also due to  slight structural differences observed among the two 
isotypes, seen predominantly in the ligand binding domain [11].  ERα and ER β have 
about 58% sequence identity on an amino acid level in their LBD with only two amino 
acids differences in the ligand binding pocket [12].  
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Estradiol Bisphenol Resveratrol 
PPT MPP Tamoxifen 
Figure 3.1 Various ligands for Estrogen Receptor α 
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ERα contains M421 and L384 which in ERβ corresponds to I373 and M336, respectively 
[13]. 
  The most extensively studied estrogen receptor, ERα, binds a wide range of 
ligands such as bisphenol and resveratrol that activate ERα as well as tamoxifen,  
propylpyrazole triol (PTT) and  methyl-piperidino-pyrazole (MPP) which act as selective 
estrogen receptor modulators (SERMs) activating ERα only in specific tissues due to 
availability of specific coactivators (Figure 3.1) [14-17]. However, many of the ERα 
ligands are derivatives of the ABCD steroidal ring system based on ERα natural ligand, 
17β-estradiol. Recently, ligands with deconstructed ABCD ring system with A-CD ring 
have also been reported. Thus, large range of compounds which selectively activate ERα 
in different tissue, make challenge for developing novel ligands for ERα, and 
understanding structure - activation relationship is essential. 
 The ligand binding pocket (LBP) of the LBD of the ERalpha contributes to the 
selectivity and function of this receptor.   The LBP formed by helices 3, 7 and 12, 
comprising a  pocket with a volume of  450 Å3, double the of volume of the 17β-estradiol 
ligand itself (Figure 3.2) [18]. In the binding of ERα ligand  with a high affinity, involves 
primarily hydrophobic interactions, as well as polar contacts created by two hydroxyl 
groups 11 Å apart. Extensive mutagenesis studies of ERα showed importance of many 
other residues in contact with ligand, including essential hydrophobic amino acids which 
interact with hydrophobic core of ERα pharmacophore [18-20]. Thus it has essential role 
for ligand selectivity and sensitivity. One of them, the phenolic hydroxyl of the A ring in 




















































































   
   
   
   
   



















Beta 3 Helix 5 
Helix 7 
Figure 3.3 ERα ligand binding pocket. The ligand, 17β-estradiol, is shown in green 
and the residues in the ligand binding pocket of ERα are colored by their corresponding 
helix. 
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353 (E353) and arginine 436 (R346) as well as a water molecule. The other hydroxyl 
group is the 17β-hydroxyl group in the D ring of the steroidal hormone, which hydrogen 
bonds to histidine 524 (H524) [18]. However, this hydrogen bond contributes far less 
towards the affinity of the ligand for the pocket [9].  
 As most NRs, the ER α undergoes conformation change by binding to an agonist. 
Thus, recruitment of RNA polymerase eventually occurs through the interaction between 
the LBD and coactivator proteins which are involved in mediating those interactions.  
The estrogen receptors are known to interact with a number of coactivator proteins, such 
as p160 steroid receptor coactivator (SRC) family of coactivators, primarily SRC-1, -2, 
and –3 are required [21]. These coactivators interact with ERα LBD by coactivator 
binding site, known as LXXXLL NR box (L is leucine and X is any amino acid) created 
on the surface by active conformation of helix 12 [22]. However, this binding site is 
available for activator only in case of agonist binding. In case of antagonist, helix 12 does 
not display active conformation to enable in recruitment of coactivator. 
 
3.2 hERα as a  Drug Target for Discovery of Fluorescent Probes 
 As previously mentioned, the wide distribution of ERα in various human tissues 
implicates this receptor in a large number of diseases, including breast cancer, 
osteoporosis and cardiovascular diseases. To date, tamoxifen, the most widely used drug 
to treat breast cancer, is an ERα antagonist [23, 24]. Due to the success of this molecule 
and others which have served as antagonists to this receptor, and also play a critical role 
as chemotherapeutic agents, a keen interest lies in developing novel ligands for ERα, as 
well as other NRs, that could serve as potential drugs for a number of NR-related 
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diseases.  Furthermore, some highly successful drugs, like tamoxifen, which are used in 
the treatment of the ER- positive breast cancer, face the issue of cells developing 
resistance, as noted in 40% of patients [25]. Thus identification of a novel class of small 
molecules as potential agonists or antagonists is a key step in developing new drugs that 
will enhance therapy for ER related diseases, and addressing the issue of resistance. 
 In addition to drug discovery, understanding the mobility patterns of the receptor 
in vivo can lead to early detection of several diseases, such as breast cancer.  As with 
most of the steroidal subclass of nuclear receptors, ERα is translocated to the nucleus 
upon binding to a ligand. Thus estrogen receptor is prominently localized in nucleus [26]. 
However, recent studies showed the presence of ERα in cytoplasm, the function of which 
is unknown and others have reported a localization of ERα in the cell membrane [27]. 
These ERs localized outside of the nucleus interact with many cell signaling molecules 
and other factors such as epidermal growth factor receptor (EGFR) that it is known to 
play a role in tamoxifen resistance by phosphorylation of ERα [25, 28, 29]. However, a 
significant amount of work needs to be accomplished to understand ERα trafficking in 
cells and its role in nuclear and non-nuclear signaling.  This could perhaps shed some 
light in early patterns of several nuclear receptor based diseases. 
 In recent years, the development of fluorescent probes has helped visualize the 
localization and trafficking of NRs inside cells. In particular, the use of the green 
fluorescent protein (GFP) from Aequorea victoria fused to specific nuclear receptors has 
provided a powerful method for detecting both function and mobility of NRs in vivo [30].   
A disadvantage to fusion proteins with respect to NRs and to their LBD is the potential 








































Figure 3.4 The structures of fluorescent ligands for ERα. 
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transcriptional regulation.  The presence of a bulky protein could hinder the 
conformational change or interface with surface protein – protein interactions necessary 
for the natural function of these receptors. More recently, studies have described various 
molecules that consist of a conjugate of the ligand and the fluorescent dye for ERα. In 
most cases the fluorescent conjugates are attached to well-known ERα ligands such as 
17-β-estradiol (E2) or tamoxifen (Figure 3.4) [31-33]. However, the bulkiness of these 
conjugates decreases the affinity of these molecules for the receptor decreasing their 
potential as drugs due to their limited activation profile [34]. Thus, despite their 
visualization properties, these compounds are unable to serve as potential ligands for 
these receptors. 
  Thus, the characterization and development of potentially fluorescent small 
molecule ligands instead of the bulky GFP fusion protein or small molecule conjugates 
serves a two-fold advantage.  Not only would these small molecules potentially serve as a 
new class of ligands for these receptors with activation profiles similar to other known 
ligands for these receptors, but the fluorescence capability of these small molecules 
would eliminate the bulkiness of a fusion protein that could distract the natural function 
of these proteins. 
 
3.3 Fluorescent Protein Chromophore Design and Molecular Modeling for hERα 
               The ERα selective FP chromophores were rationally designed using the 
arylmethyleneimidazolidinone (AMI) core to resemble the ABCD ring system of steroids 
(Figure 3.5). As mentioned previously, most of the estrogen selective ligands are based 
on the classic steroid ring system. However, most of these compounds induce side effects  
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Figure 3.5 Creating chromophores for Estrogen Receptor α. 
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involving the increase of the risk cancer or vascular problems. Thus, development 
compounds with removed B – ring from ABCD steroid structures brought new avenue 
for novel selective ERα ligands. These compounds have shown to bind to receptor with 
similar affinity as estradiol. The A-CD ring system compounds could prevent formation 
of undesirable metabolites, ortho-quinones, which are linked to estrogen-related 
carcinogenicity [35, 36].  In addition removal of B-ring increases the compound 
flexibility. 
               By analyzing the base AMI structure, a resemblance was noted to the ACD core 
structure of several ER ligands. Thus, ER selective AMIs were designed to not 
incorporate at a B ring, by analogy to other known estrogen receptor agonists 
incorporating only the A-CD ring system [35, 37]. In analyzing the AMI core, a phenolic 
aryl group was retained to play a role analogous to the functionalized ring A of the 
steroid molecule and create crucial contacts with E353. The obligatory imidazolidinone 
group in the AMI structure was designed to mimic the C ring of a steroid molecule, and 
alkyl substituents around the heterocycle (R1) were employed to mimic for the absent 
steroidal D ring. A series of such derivatives was designed based on this core structure, 
with the addition of substituents to create potential ligands for ERα. The ability of the 
designed chromophores to mimic the overall interaction of the heterocyclic core of 
various ERα ligands was determined via molecular modeling.  AMI 4 was docked into 
the crystal structure of the ERα ligand binding domain (1ERE) using AutoDock Vina, the 
software which predict of fit and interactions of small molecules with binding site of the 
protein [38]. It samples of different conformations of ligand in rigid binding site of 








Figure 3.6 Structures of the AMIs ligands docked into the crystal structure of  
                   hERα (pdb:1ERE) using the software Autodock Vina. A) 4, B) 1 
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overlayed with crystal structure of estradiol and showed binding to ERα with favorable 
superimposition with estradiol. In addition, modeling showed that the phenolic group, 
superimposed on the A ring of estradiol (E2), created an analogous hydrogen bond with 
glutamate E353 and arginine R394 (Figure 3.6A), analogous to estradiol. It has been 
shown that these interactions are crucial for binding and activation of estrogen receptor 
by most of ligands. However, the same calculations failed to overlay the imidazolidinone 
ring of the AMI compound with the C ring of estradiol. This is probably due to free 
rotation between the phenyl and the imidazolindinone ring, which is crucial for the 
fluorescence of these AMIs, as previously reported [39, 40]. Based on the docking results 
and examination of known structures with ERα agonists, additional compounds were 
designed with potential hydrogen bonding between the ligand and the histidine at 524 
(H524). Histidine H524 is known to form a hydrogen bond with the 17-β hydroxyl group 
on the D-ring of E2 (Figure 3.6B) [18]. From this, addition of a polar group such as the 
hydroxyl group as in compound 3 or a carboxyl group in compound 1 and 2 could 
provide the additional hydrogen bond, based on the in silico modeling results, increasing 
the probability of ligand binding and activation. 
 Despite the advantages of molecular modeling as a tool for visualizing protein-
ligand interactions, such calculations are limited in elucidating the importance of specific 
substituents. Therefore, additional AMI molecules with various substituents were 
designed, synthesized, and tested based on chemical properties, such as hydrogen 
bonding and hydrophobicity, as well as shape and volume of these potential ligands 
(Table 3.1). The various activation profiles could indicate a correlation between the 
structures of moieties and ligand binding with ERα. 
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Table 3.1 Structures of AMIs 
AMI R1 R2 R3 R4 R5 
1 C3H6CO2H H H OH H 
2 C5H10CO2H H H OH H 
3 C3H6OH H H OH H 
4 C3H7 H H OH H 
5 C3H6CO2H H H H H 
6 CH3 H H CH3 H 
7 CH3 H H H H 
8 CH3 H CH3 OH CH3 
9 CH3 H H N(Me)2 H 
10 C5H11 OH H N(Me)2 H 
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3.4 Evaluating Fluorogens via Chemical Complementation 
 
 Genetic selection system is powerful tool for protein engineering and drug 
discovery due to the possibility of evaluation the protein – small molecules interactions. 
Chemical complementation as genetic selection system in yeast is fast and feasible 
powerful tool for detection interactions between nuclear receptor and small molecules, 
ligands. 
  Chemical complementation is a semi high-throughput selection, where the 
survival of an engineered yeast (Saccharomyces cerevisiae) strain, PJ69-4A, is linked to 
the ability of a small molecule ligand to activate a nuclear receptor [41-43]. PJ69-4A 
contains Gal4 response elements (Gal4RE) controlling expression of the genetic selection  
genes, HIS3 and ADE2, involved in the histidine and adenine biosynthetic pathway, 
respectively. Two fusion proteins consisting of the Gal4 DNA binding domain (GBD) 
fused to the ERα LBD (GBD: ERα LBD) is transformed into yeast along with the fusion 
protein of the NR coactivator fused to Gal4 activation domain (GAD). Upon ligand 
binding to the ERα LBD, the GBD: ERα LBD fusion binds to Gal4RE, recruiting the  
coactivator, the GAD fusion protein. Thus the GAD serves to recruit the yeast 
transcriptional machinery required to initiate transcription of the selection gene (ADE2 or 
HIS3) [42]. Activation of the selection gene, such as the HIS3 gene, enables the yeast 
strain to grow on media lacking histidine in the presence of the ligand (Figure 3.7). Thus, 
the survival of the yeast depends on the presence of the small ligand molecules. 
 Ten synthetic AMI ligands (Table 3) were tested in chemical complementation. 













Figure 3.7 Scheme of chemical complementation assay.  
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SRC-1: GAD was observed in histidine selective media at (SC-HLW with 1 mM 3AT), 
containing 10 µM of AMI, and 3-amino-1,2,4-triazole (3AT), an inhibitor of 
imidazoleglycerol-phosphate dehydratase was added to reduce basal expression observed 
due to “leaky” HIS3 gene [44].  As shown in Figure 3.8, yeast expressing Gal4 ligand 
independent factor displayed growth as expected. As a positive control, yeast expressing 
ERα, were incubated with 17-β estradiol (E2).  As shown in Figure 3.8, ligand activated 
growth was observed with E2 and Gal4 as expected. AMI 1 and 2 also showed slight 
ligand activated growth (two-fold activation based on growth) and low sensitivity (EC50 
>10µM) with ERα. However, most of the tested ligands did not induce growth in yeast, 
indicating that the ligand was unable to bind and activate the receptor, allowing the yeast 
to survive. This data indicated that designed AMI is able to bind and activate slightly 
ERα in yeast.  
 
3.5 hERα activation by fluorogens in mammalian cells 
 To determine whether a similar trend in activation seen in yeast is observed in 
mammalian cells, the fluorogens were analyzed for activation and fluorescence in human 
embryonic kidney 293T cells (HEK293T). The Gal4 DNA binding domain fused to the 
ERα ligand binding domain (GBD: ERαLBD) was cloned into a mammalian expression 
vector (pCMX) containing a cytomegalovirus (CMV) promoter. Using a luciferase 
reporter gene assay, HEK293T cells were co-transfected with a reporter plasmid 
containing the Renilla luciferase gene under the control of Gal4 response elements. Cells 
were transfected with the two plasmids and various chromophores were added and tested  
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Figure 3.8 Chemical complementation in yeast. Results of chemical 
complementation in histidine selective media (-HLW) with 1mM 3-AT. The 
ligand concentration of 10 µM was used. Gal4 is a ligand independent 
transcription factor and is used as a positive control. ERα with estradiol (E2) 




for luciferase activity at concentration of 10 µM. Luciferase activity is an indicator of 
binding and activation of nuclear receptor by small molecule. 
 To evaluate interaction of AMIs with ERα in mammalian cells, library of 
synthesized AMIs was tested for ERα activation. Cells expressing receptor were 
incubated with 10 µM of a library of 46 AMIs and tested for luciferase activity. As a 
control, the receptor was tested with the E2 ligand, and as expected, ERα was activated 
by E2. As shown in Figure 3.9, AMI 1 and 2 activated ERα displaying 6-fold activation. 
However, there are few compounds, AMI 4, 49, 94 and 97 and 108 which activated ERα 
with 5 fold activation, in comparison to the 14-fold activation with E2. However, based 
on the previous results achieved in yeast, our studies were focused on AMI 1 and 2 and 
its derivatives. 
 The ten synthetic AMI chromophores were tested with ERα at a concentration of 
10 µM or in the absence of ligand. The highest activation was observed with 
chromophores 1-4, 8 and 9 displaying an approximately 10-fold activation as shown in 
Figure 3.10A, in comparison to the 21-fold activation observed with E2. To determine the 
EC50 values of these compounds, a dose response curve was generated for each 
compound. As seen in Figure 3.10B, compounds 4, 8 and 9 showed the highest sensitivity 
with an EC50 of 3 µM whereas compounds 2, 3 and 4 displayed EC50 > 3 µM.  
Compounds 5, 6 and 7 showed no activation.  Despite the fact that these compounds had  
a higher EC50 value and lower activation in comparison to ERα and estradiol (873 pM), 
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Figure 3.9 Activation profile of AMIs in ERα. Part I. ERα (GBD: ERαLBD) was 
transfected into HEK298T cells with p17*4TATALuc plasmid, a luciferase reporter 
gene under the control of Gal4 response elements and were incubated with 10 µM 
of ligand. Red line indicates the E2 activation level. Structures of all above the 

















Figure 3.9 Activation profile of AMIs in ERα. Part II. ERα (GBD:ERαLBD) 
was transfected into HEK298T cells with p17*4TATALuc plasmid, a luciferase 
reporter gene under the control of Gal4 response elements and were incubated with 
10 µM of ligand. Red line indicates the E2 activation level. Structure of all above 


























 These results confirm initial hypothesis, based on molecular modeling, that a key 
moiety for binding of ERα LBD is the hydroxyl group of the phenyl ring of AMI, which 
could potentially form a hydrogen bond with E353 and R394. Compounds 5, 6 and  
7, lacking a hydroxyl group at that position, did not display activation of the estrogen 
receptor. The importance of creating polar contacts with H524 has also been taken into 
account. Thus, the chromophores must include a substituent R1 on the imidazolidinone 
ring. Hydrogen-bonding moieties on the alkyl group can potentially lead to an interaction 
with H524. However, such polar groups do not seem essential for activation. This is 
evident with 8, lacking this group, which displays the same sensitivity as 1 containing a 
carboxyl group at this position.  This substitution activity is noted for 3 with a hydroxyl 
group and 1 and 2 with carboxyl groups, which show the same degree of activation. A 
main feature of chromophore design is that the length of the alkyl group has little 
influence on sensitivity. Chromophore 1, which lacks two carbons in the alkyl chain 
compared to 2, has only slightly higher activation than 2. Another factor that might 
contribute to increased sensitivity to ERα is the presence of substituents in positions R3 
and R5. Conversely, with methyl groups in these positions, 8 shows higher sensitivity, 
similar to that of 1. These groups can possibly play a role in hydrophobic interactions 
with non-polar residues in the binding pocket. In addition, substitutions at these positions 
may reduce the flexibility between the phenyl and imidazolindinone rings that can lead to  
a more planar conformation of the chromophore, similar to the enforced conformation of 




Figure 3.10 Activation profile of chromophores in mammalian cells (HEK293T), A. 
Relative inductions of ERα in the presence of 10μM of each ligand B. Dose response 
curves for the activation of ERα (Gal4DBD: ERαLBD)  in response to various 
concentrations of 1,3, 4, 8, 9. Activity is measured in relative light units (RLU) derived 
from the measurement of luciferase activity and normalization against a β-galactosidase 
internal standard.  
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3.6 Visualization of hERα in  yeast and in mammalian cells using Fluorescent 
Chromophores 
As mentioned previously, a goal of developing AMIs as novel ligands was to 
determine if fluorescence would be observed upon binding to the NRs. The 
chromophores were tested for fluorescence in the presence of ERα in yeast and NIH3T3 
mammalian cells. The chromophores were then tested in yeast for fluorescence, where 
yeast cells containing ER, along with the Gal4 control were exposed to the 
chromophores, along with estradiol as a negative control.  In the presence of the ER and 
both chromophores AMI 1 and AMI 2, yeast cells displayed fluorescence, showing much 
higher in intensity with AMI 1 than with AMI 2 (Figure 3.11). The amount of 
fluorescence observed with AMI 2 was higher in comparison to cells containing ER and 
estradiol.  As a method of assessing basal fluorescence, yeast cells containing the Gal4 
protein, a ligand-independent yeast transcriptional factor, was visualized where no basal 
fluorescence was observed.   
 The next step was to determine whether a similar trend in activation and 
fluorescence seen in yeast would be observed in mammalian cells.  Confocal microscopy 
was used to monitor cellular uptake and localization of the chromophores in the cell. The 
cells were transfected with the mammalian expression vector pCMXGhERLBD 
expressing Gal4DBD:ERαLBD fusion protein and incubated in media in each of the ten 
chromophores. To determine the amount of background fluorescence observed with cells  
and the compounds, a series of negative controls were employed. First, the NIH3T3 cells 
transfected with ERα were exposed either to no ligands or to estradiol alone, addressing  
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         Figure 3.11 Imaging of yeast cells with the fluorescent chromophores. Yeast cells              
         expressing ERα (Gal4DBD: ERαLBD) were incubated with 1 and 2. As a negative control  
         cells lacking ERα were incubated with 2. 
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the basal fluorescence observed due to the cells and in the presence of ERα. Cells lacking 
ERα were also exposed to the AMI compounds, addressing the potential fluorescence due 
to non specific binding of the fluorophore to endogenous proteins. 
 As shown in Figure 3.12 slight basal fluorescence was observed in the case of one 
of the controls--cells lacking ERα and incubated with compound 10. In the presence of 
ERα, 6 of 10 of the chromophores showing activation displayed no fluorescence (data not 
shown). However in the case of compound 10, fluorescence was observed in the 
cytoplasm of the NIH3T3 cells, despite the absence of activation. Perhaps, this 
observation suggests that activation and fluorescence can be independent of each other.  
  In other words, these chromophores could serve as agonists that bind, activate and 
display fluorescence. Conversely, in other instances these compounds can bind and 
fluoresce but not activate, similar to a traditional antagonist. The localization of the 
observed fluorescence in the cytoplasm of the cell was also unexpected due to the fact 
that previous research and findings have shown ERα localizes to the nucleus in the 
presence of agonist or an antagonist [45]. However, Rickert et al have recently shown 
that OHT- derived conjugates display fluorescence in cytoplasm. It remains unexplained 
why these compounds are not able to be transported to nucleus [33]. 
 
3.7 Materials and Methods 
 
Synthesis of ligands  
 Synthesis of the ligands was carried out using previously described synthetic 
methods in Chapter 2.  For compounds 1-3 and 5 the Schiff base was obtained by  
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ERα + 4 ERα + 10 no ERα + 10 
Figure 3.12 Imaging of NIH 3T3 cells with the fluorescent chromophores.  
Mammalian cells expressing ERα (Gal4DBD: ERαLBD)  were incubated with 4 and 




reacting the aromatic aldehyde (1eq), the primary amine (1eq) and sodium hydroxide 
(1.1eq) in 40.0 mL of MeOH at reflux for 4hr, followed by removal of solvent under 
reduced pressure to yield product.  For 4 and 6-9 the aldehyde (1eq) and primary amine 
(1eq) were allowed to stir 12 h, yielding pure product.  The imidate was prepared as 
previously described [46]. Imidazolidinones were synthesized by combining the 
corresponding Schiff base with the imidate and ~0.5mL of MeOH with stirring for 12 h 
which resulted in precipitate formation for 4 and 6-9.  Solvent removal from compounds 
1-3 and 5 under reduced pressure provided solid products as nearly pure materials.  All 
products were further washed with cold Et2O to yield the desired products as light yellow 
crystalline materials. 
 
In Silico Docking Studies 
 Modeling of ligand–protein complexes was carried out with AutoDock Vina® 
using the estradiol–ERα ligand binding domain (pdb: 1ERE) crystal structure under 
standard parameters. The estrogen receptor was prepared for docking via UCSF 
CHIMERA, an interactive molecular graphics program, by removing the ligand and 
water molecules, adding polar hydrogens, and assigning Kollman united atom charges 
[47]. Ligands were created using ChemBioDraw Ultra 11.0 / ChemBio3D Ultra 11.0 
(Cambridge Soft, USA) and were minimized using MMFF94 force field.  Ligands were 
modified with the AutoDockTools by adding Gasteiger charges to set the partial charge 




Liquid quantification assay in yeast 
 Variants were tested in liquid quantification assays in 96-well plates with media 
lacking histidine, leucine, and tryptophan (SC-HLW), 0.1 mM 3AT, and with or without 
chromophores or 17β-estradiol at varying concentrations.  Media and cells were added in 
a 4:1 ratio into 96-well plates.  Plates were incubated at 30°C, with shaking at 170 rpm.  




 HEK293T cells (ATCC, USA) were transfected with the plasmid 
pCMXwthERαLBD.  This plasmid contains the Gal4DBD (GBD) fused to the wild-type 
ERα ligand binding domain LBD (GBD:LBD fusion under the control of a 
cytomegalovirus (CMV) promoter).  The reporter plasmid, p17*4TATAluc, contained the 
Renilla luciferase gene under the control of four Gal4 response elements located 
upstream from a minimal thymidine kinase promoter. The pCMXβgal, a plasmid 
containing the β-galactosidase gene under the control of the mammalian CMV promoter, 
was also used as an internal standard. Lipofectamine 2000 (Invitrogen, USA) was used as 
the cationic lipid and transfection experimental details are described in Taylor et al.[49]  
Ligands were added to the wells at various concentrations.  Cells were harvested and 
analyzed for luciferase and β-galactosidase activity.  All data points represent the average 






 Transfection of NIH3T3 cells was performed in a single plate with PolyFect 
(Qiagen, USA) transfection reagent according to the manufacturer’s protocol. Plasmids 
pCMXwthERαLBD expressing Gal4DBD:ERαLBD fusion protein and mCherry-nuc as 
control were co-transfected into NIH3T3 cells.  After 8 hours of transfection at 37˚C in 
humidified air with 5% CO2, the media in the wells was removed and ligand (10mM) was 
added with the media to the wells. Cells were then subjected to microscopy after 30 hours 
of incubation. Samples were washed with 1X PBS and confocal imaging was performed 
using a Zeiss LSM 510 NLO w/META MPE confocal microscope (Carl Zeiss 
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FLUOPHORES AS LIGANDS FOR THE PREGNANE X RECEPTOR 
  
4.1 Pregnane X Receptor (PXR) 
 The pregnane X receptor (PXR; gene designation NR1I2) is a member of the 
nuclear receptor superfamily and is expressed in liver and intestine [1, 2]. PXR regulates 
the expression of number of enzymes involved in xenobiotic metabolism and transport of 
various drugs, endogenous substances and environmental toxins [3, 4]. PXR is involved 
in the regulation of several cytochrome P450s, and one of its main targets is cytochrome 
P450 monooxygenase 3A4 (CYP3A4), which has a major role in the biotransformation of 
drugs and catalyzes the metabolism of 60% of all drugs that are in use, such as 
contraceptive steroids, immunosuppressive agents and some antibiotics [5]. In addition to 
regulation of the CYP3A4 gene, PXR regulates the expression other target genes, 
including glutathione S-transferases, sulfotransferases, uridine 5′-diphosphate 
glucuronosyltransferases (UGTs) and drug transporters such as  P-glycoprotein and 
multi-drug resistance-associated proteins 2 and 3 [6-8]. This nuclear receptor has been 
implicated in various physiological and pathophysiological processes, such as glucose 
and bone homeostasis, lipid metabolism, inflammatory response and apoptosis in cancer 
[9-12]. 
 Structurally, similar to other NRs, PXR contains both DNA-binding domain 
(DBD) and ligand binding domain (LBD) connected by a flexible hinge region [13]. The 
PXR DBD is highly conserved with 95% amino acid identity in nuclear receptor 
superfamily [14]. As with other nuclear receptors, PXR forms a heterodimer partner with 
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the retinoid X receptor (RXR). However, the PXR LBD is highly divergent across 
species, compared to other nuclear receptors. The LBD between mammalian and non-
mammalian PXR sequences, shares only approximately 50% identity on the amino acid 
level and 80% between mammalians PXR [15, 16].  The human PXR LBD, similar to 
other nuclear receptors is arranged into three-layered α helical sandwich with five 
stranded anti-parallel β- sheets, unique to PXR (Figure 4.1) [17]. These extended β –
sheets has been shown to take a crucial role in mediating dimerization and even more 
importantly, contributes to the binding capabilities of this receptor in comparison to other 
nuclear receptors [18].  
 Several crystal structures of PXR with different ligands bound to the PXR LBD 
revealed unique ligand binding pocket. The large, hydrophobic and flexible PXR ligand 
binding pocket is able to accommodate a wide range of ligands, expanding to 1200 Å3. 
This pocket size accommodates the binding of ligands varying in mass from 232 Daltons 
(Da) of phenobarbital to 823 Da of rifampicin [16, 19, 20]. The promiscuity of this 
receptor is in part due to the fact that structurally this receptor contains additional β- 
sheets, allowing for a larger binding pocket in relation to other nuclear receptors.  The 
PXR ligand binding pocket besides the flexibility is also mostly hydrophobic. Of the 28 
residues present in the ligand binding pocket (LBP), 20 of these residues are  
hydrophobic, contributing largely to its ability to bind and activate in response to 
hydrophobic ligands [21]. Many of the PXR ligands contain a partition coefficient in 
range logP 3.5 – 10, indicating the  hydrophobic character of ligands [19]. 
 Flexibility, hydrophobicity and the additional two β- strands are major factors 
which contribute to promiscuity of PXR and allow for binding a large range of ligands.  
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Figure 4.1 Crystal structure of PXR LBD with rifampicin (Pdb:1SKX). Β-stands 
are shown in red and rifampicin is shown in orange with yellow space filling.  
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However, PXR’s promiscuity is also in part contributed to a flexible loop that is 
connected to ligand binding pocket by a nonsolvent – accessible pore. This flexible loop 
allows for the opening of the pocket to accommodate larger compounds, such as the 
antibiotic rifampicin [17, 21]. This is particularly important since PXR serves as 
axenobiotic sensor. This receptor is known to bind a number of structurally diverse 
ligands, such as the cholesterol-lowering drug SR12813, anticancer compounds, herbal 
components (e.g. St. John’s Wort), plant extracts and HIV protease inhibitors (e.g.  
indinavir and ritonavir) (Figure 4.2) [22-25]. The PXR activation by above mentioned 
drugs implies that this nuclear receptor in clinically important for drug-drug interactions 
(Figure 4.3). For example, use of St. John’s Wort causes upregulation of cytochrome 
P450 due to PXR activation, which in turn reduces the serum levels of several drugs 
including antiviral indinavir, immunosuppressant ciclosporin and oral contraceptives [26-
28]. Despite its promiscuous behavior, a certain amount of specificity is also observed in 
the binding properties of this receptor.  Specific atoms are known to influence the binding 
and activation properties of this receptor, often referred to as direct promiscuity.  
 
4.2 Evaluating Fluophores Interaction with the PXR in mammalian cells 
 As previously described in Chapter 3, the goal of this work is development of 
novel ligands based on the structure of the chromophore of the green fluorescent protein 
(GFP), the arylmethyleneimidazolodinone (AMI), for various nuclear receptors with 
fluorescence ability. Successfully, we have developed novel AMIs for estrogen receptor 
α. To date, there is lack of fluorescent ligands for PXR which will be able to fluorescence 
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development of specific ligands for PXR could be beneficial for treatment PXR related 
diseases. Based on these previous results we decided to evaluate interaction of AMIs with 
the pregnane x receptor.  It had been shown that PXR is activated by several ERα ligands, 
such as 17-β estradiol and tamoxifen, and because of their similar ligand binding profiles, 
the thought was that certain AMIs that activate ER, could potentially activate PXR. In 
addition to being potential ligands, AMIs are designed to fluoresce upon binding PXR, 
leading potentially to the development of the first fluorescent ligands, serving as a 
powerful visualization tool for this receptor in vivo. Human embryonic kidney 293T cells 
(HEK293T) were used to determine the activity of the AMIs with PXR in vivo.  The cells 
were transfected with a mammalian expression vector (pCMX) containing the Gal4 DNA 
binding domain fused to the PXR ligand binding domain (GBD:PXRLBD). The cells 
were also co-transfected with a reporter plasmid, which contained a luciferase reporter 
gene assay under the control of Gal4 response elements. Transfected cells were incubated 
with the AMI derivatives at 10 µM and tested for activation by measuring luminescence. 
In the presence of ligand binding to the receptor, the interaction of the Gal4 DBD with 
Gal4 response element, allows for luciferase expression, hence leading to luminescence.  
  As shown in Figure 4.4, cells expressing PXR are able to active this receptor in 
the presence of the rifampicin, the known PXR ligand which was used as a control. 
However, ERα AMIs, numbered 1 through 9, derivatives did not display any activation 
with PXR as we expected. However, these results confirmed that the AMI compounds 
selectively activated ERα.  
 Next, we decided to determine if modifications to the AMI core could lead to the 











































AMI R1 R2 R3 R4 R5 
1 C3H6CO2H H H OH H 
2 C5H10CO2H H H OH H 
3 C3H6OH H H OH H 
4 C3H7 H H OH H 
6 CH3 H H CH3 H 
8 CH3 H CH3 OH CH3 






















Figure 4.4 Activation profile of ER AMI to test for PXR activation. 
HEK298T cells were transfected with plasmid expressing hybrid 
(GBD:PXR) and reporter plasmid. Rifampicin used as a control. Luciferase 










































Figure 4.5 Activation profile of 60 AMIs in PXR. Part I. PXR 
(GBD:PXRLBD)was transfected into HEK298T cells with p17*4TATALuc 
plasmid, a luciferase reporter gene under the control of Gal4 response elements 
and were incubated with 10 µM of ligand. Structure of all above ligands are 
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Figure 4.5 Activation profile of 60 AMIs in PXR. Part II. PXR 
(GBD:PXRLBD)was transfected into HEK298T cells with p17*4TATALuc 
plasmid, a luciferase reporter gene under the control of Gal4 response elements 
and were incubated with 10 µM of ligand. Structure of all above ligands are 
included in appendix. 
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tested in HEK293T cells as described above. As shown in Figure 4.5 rifampicin and 
T0901317 served as controls, since these two ligands were previously shown to activate 
PXR and this was consistent with our results as these compounds both display 90 and 64 
fold activation, respectively.  Of the 60 compounds shown, 17 compounds displayed 
activity with PXR. Some of these compounds have showed similar activity of 70 – 100 
fold activation in comparism to rifampicin and T090 (90 and 64 fold activation, 
respectively), the known PXR activators.  
 
4.3 Analysis of PXR activation by AMIs 
 The results that were obtained through screening the AMI library indicated that 
several of these AMIs could serve as agonists for PXR.  In certain instances, as seen with 
AMI 112 and 116 the fold activation observed with these molecules were higher than that 
observed with rifampicin.  Furthermore, in looking closer at the structure of these 
compounds, the AMIs could be grouped based on their chemical properties forming four 
main groups, refereed to as groups A-D, as shown in Figure 4.6 and in Table 4.1.    
 These groups indicate a specific preference of the receptor for a variety of 
substituents on the core of the AMI structure. Two of these groups, A and B, are 
characterized by diethylamine group at position R4 that seems to have a direct effect on 
increase the activation level. The highest activation level is achieved by group A (AMI 1-
8) which has additional hydroxyl group at position R2 on the core of the AMI structure. 
Interestingly, in comparing this group of compounds to group B (AMI 9-12), we are able 
to see that the lack of the hydroxyl group seems to be causing a two fold decrease in 













































Figure 4.6 Activation profile of PXR with various AMIs. AMIs were categorized on 4 
classes based structure similarity. Group A is presented in purple, group B in blue, group 
C in turquoise and group D in orange.   HEK293T cells were transfected with a luciferase 
reporter gene and expression plasmid encoding fusion of Gal4DBD and LBD of PXR. 
Transfected cells were treated with 10 µM compounds for 30h. Rifampicin (RIF) and 
T090 were used as references. DMSO is used as a negative control. 
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Table 4.1. Structures of Fluorescent Protein Chromophores 
Compound R1 R2 R3 R4 R5 
1A CH3 OH H N(Et)2 H 
2A C3H7 OH H N(Et)2 H 
3A C5H11 OH H N(Et)2 H 
4A C6H13 OH H N(Et)2 H 
5A C7H15 OH H N(Et)2 H 
6A C8H17 OH H N(Et)2 H 
7A C10H21 OH H N(Et)2 H 
8A C3H6CO2H OH H N(Et)2 H 
9B C3H7 H H N(Et)2 H 
10B C5H11 H H N(Et)2 H 
11B C6H13 H H N(Et)2 H 
12B i-C3H7 H H N(Et)2 H 
13C CH3 Br H H H 
14C C3H7 Br H H H 
15C C3H7 Cl H H H 
16D  CH3 H C(CH)3 OH C(CH)3 











 To further analyze the individual compounds in each of the groups, each of the 
AMIs were further tested in a dose-response fashion for activation with PXR. To 
determine the sensitivity of these derivatives a subset of the best activators of PXR were 
tested for their efficacy in a dose-response assay, with AMI concentrations ranging from 
10 nM to 10 µM, in order to calculate EC50 values, the effective concentration required to 
reach 50% of maximum activation. As shown in Figure 4.7B, most of the compounds 
displayed a sensitivity profile between 3-7 µM, comparable to that of rifampicin (EC50 ≈ 
1.3 µM). Thus, these AMI derivatives are similar in sensitivity but show higher activation 
levels than rifampicin, making these compounds a novel and potential class of PXR 
agonists. 
 The activation observed with the various AMI derivatives can be correlated with 
the presence of certain R-groups around the core structure of the molecule.  In particular, 
the size of the alkyl chain at position R1 seems to have a direct effect on the activation 
level.  As observed with AMI derivatives 1-8, a variety of alkyl chain sizes produced 
activation profiles similar or greater than rifampicin (EC50 ≈ 1.3 µM, 100 fold activation), 
but the hexyl chain (AMI 4) displayed the greatest activation with a 180-fold activation 
and an EC50 value of 6.3 µM.  This observation confirms the promiscuous and shape- 
sensitive nature of the PXR. As indicated previously, the activation profiles of these AMI 
derivatives provides some insight into the structure/function relationship between PXR 
and different ligands.  First, the presence of a diethylamino group at R3 position, as seen 
in AMI (1-8), seems to be important for activation since AMIs, which lacks this 
functional group at R3 position, displays no activation. In addition, hydrophobic contacts 




Figure 4.7 Activation profile of class A of AMIs. A. PXR (GBD:PXRLBD) 
transfected into mammalian cells HEK298T and incubated with 10µM ligand 




















but within the limits imposed by the volume of the alkyl chain.  The activation observed 
with AMI 4, with six carbons, was almost twice that of rifampicin (Eff4 = 172%) as 
shown in Table 4.2, while larger and smaller alkyl groups produced lower activation. 
Compounds 5 and 6 (Eff5 = 159%, Eff6 = 125%) display slightly lower fold activation 
compared to 4 differing by one or two carbons in the alkyl chain. However, the 
compound 2 displays almost one third of fold activation reached by 4. These results 
suggest that optimal length of alkyl chain for activation is six carbons to obtain maximal 
activation with PXR. More than eight carbons in this position lead to a drastic decrease in 
the activation, as seen in the case of chromophore 7 (Eff7 = 26%). The presence of a 
methyl group does not lead to activation as seen with compound 1. This suggests that 
probably alkyl group takes place in creating of key hydrophobic contacts in the binding 
pocket. This hydrophobic volume effect is reminiscent of other volume-sensitive effects 
on AMI fluorescence within hydrophobic cavities and human serum albumin (HSA) 
earlier reported in literature. It has been shown that increased length of alkyl chain of 
AMIs had additional effect not only on binding but also on fluorescence level [31-33]. 
Finally, the differences in activation for AMI 2 and AMI 8, which differ only by the 
presence of a terminal carboxyl group, emphasize the importance of hydrophobicity.  
  The activity observed with group B of the AMIs derivatives displays a 
significantly lower activation profile when compared with group A described above. As 
seen in Figure 4.8 AMI (9-12) obtain the highest activation level in case of compound 11 
(Eff = 103%, EC50= 5.4 µM) same as in group A compound 6 (Eff = 172%, EC50 ≈ 5 













Compound Eff (%) EC50 (µM) MW (Da) logP MolSurf (Å2) 
Rif 100±5 1.3 823 3.85 1198 
1A 15±8 5.4 287.36 1.77 442 
2A 64±4 5 315.4 2.64 506 
3A 114±5 5.6 343.46 3.53 567 
4A 172±2 6.3 357.5 3.98 596 
5A 159±10 5.9 371.5 4.42 626 
6A 125±7 5 385.5 4.87 656 
7A 26±7 6.4 413.6 5.76 722 
8A 10±3 6 359.4 1.77 543 
9B 71±4 5.9 315 2.64 506 
10B 46±6 3 343.5 3.53 567 
11B 103±2 5.4 357.5 4.28 587 
12B 31±19 3.4 313.4 3.31 524 
13C 29±11 4.5 279 2.02 302 
14C 77±5 4.3 307.2 2.9 365 
15C 15±9 3 262.7 2.73 362 
16D  105±19 5.1 328.4 4.03 547 
17D 91±12 5.8 404.5 5.76 654 
Table 4.2. Biological activities of RARα agonists and their selected physical/chemical properties. 
Rifampicin (Rif) was used as reference and set to 100% efficacy at concentration of 10 µM. Strong 
PXR activators (activation higher than rifampicin) are indicated in red color, moderate activators in 































Figure 4.8 Activation profile of class B of AMIs. A. PXR (GBD:PXRLBD) 
transfected into mammalian cells HEK298T and incubated with 10 µM ligand 















 optimal length of alkyl chain for activation is six carbons to obtain maximal activation in 
group A as in group B. Perhaps the hexyl chain creates optimal hydrophobic contacts in 
the pocket, higher or lower number of the carbons in the alkyl chain does not allow for 
AMI to obtain specific conformation to get higher fold activation. Same as in group A, 
the decreased number of carbons caused significant lower activation level in compound 9 
and 10. This suggests that hydrophobic volume of AMIs is important for activation level. 
This data indicates that hydroxyl group at position R2 of AMI core is crucial for receiving 
higher activation. The most probably this polar group is responsible for creating contact 
with one of the polar residues in the ligand binding pocket.  When looking at groups C 
and D which contain completely different substituents on the core of the AMI structure, 
there are varying results observed. Group C includes three compounds that have halogens 
incorporated in the AMI core. Previously, several ligands with halogen moieties such as 
metachlor, oxadiazon and propiconazole were reported to be PXR agonists [34]. As 
observed in Figure 4.9, the highest level of activation was achieved by compound 14 
which has bromine in position R2 of the AMI core. In addition, the data suggests again 
that length of alkyl chain in position R1 is significant for activation level. Compound 13 
(Eff = 29%, EC50= 4.5 µM) shows two-fold decrease in activation in comparison to 
compound 14 (Eff = 77%, EC50= 4.3 µM). However, presence of chlorine in same 
position results in decreased activation as seen in AMI 15 (Eff = 15%, EC50= 3 µM)). 
The most probable cause of this behavior is the difference in the sizes of chlorine and 
bromine atoms and difference in electrostatic surface potential which could influence the 




Figure 4.9 Activation profile of class C of AMIs. A. PXR 
(GBD:PXRLBD) transfected into mammalian cells HEK298T and 
incubated with 10µM ligand B. Dose response of the best AMIs with PXR 
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However, the best compound AMI 14 shows only 45% of activation achieved by the best 
AMI PXR activator, AMI 4. 
 In Group D, two compounds showed activity with PXR. The structures of these 
AMIs are interesting due to the presence of the 2,6-di-tert-butylphenol moiety, which is 
present in the  SR12813 (EC50 = 200 nM), the cholesterol lowering drug known to 
activate PXR (Figure 4.10) [17, 35]. As seen in Figure 4.11 compound 16, the best 
activator of group D displays activation level similar to rifampicin (Eff16 =105%, Effrif = 
100%). However, compound 17, which has additional moiety, the benzene in position R1, 
displayed the reduced activation (Eff17 = 91%) in compare with 16 (Eff16 =105%). These 
results suggest that moiety of known well agonists can be successfully incorporated into 
the core of AMI and show comparable activation.  
 The differences in activation profiles with PXR and the various AMI groups 
indicate that the length of the alkyl chain and activation show a correlation.  In addition 
to the length of the alkyl chain, the presence of the 2,6-di-tert-butylphenol moiety seemed 
to show activation  and different chain length, potentially could  display higher activation 
than rifampicin. Thus AMIs 130, 131 and 132 were synthesized with three, five and six 
carbons in alkyl group in position R1, respectively. As shown in Figure 4.12 AMI 130 has 
similar sensitivity as rifampicin. AMI 131, 132 and 17 has higher sensitivity than 
rifampicin. Particularly, AMI 131 has similar profile as AMI 17 but it has slightly higher 
sensitivity. As predicted, length of the alkyl chain has influence on activation. The 
highest sensitivity was obtained with AMI 131 which has five carbons in the alkyl chain. 















































Figure 4.10 Design of PXR AMI based on ligand SR12813. Presence of  the 













































Figure 4.11 Activation profile of class D of AMIs. A. PXR (GBD:PXRLBD) 
transfected into mammalian cells HEK298T and incubated with 10µM ligand 




Figure 4.12 Activation profile of class D of AMIs. PXR (GBD:PXRLBD) 
transfected into mammalian cells HEK298T and incubated with wide range of 
concentration of AMIs. 
AMI 17 AMI 130 
AMI 131 AMI 132 
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Thus, hydrophobicity increased with length of the alkyl chain and volume is essential for 
PXR ligands to achieve activation. 
 The above results show activation of PXR by AMI compounds in cell culture 
using GBD:PXRLBD construct, containing the Gal4 DNA binding domain fused to the 
PXR ligand binding domain. However, this fusion is not present in the human body and 
potential activators for PXR as potential drugs should be also tested in their natural state. 
In the human body, PXR forms heterodimer with the retinoid x receptor α (RXR α). To 
confirm that PXR AMIs can act as agonists, full length PXR and RXR were tested for 
activation using AMI 3. The HEK298T cells were transfected with the plasmids 
containing full length RXR (pCMXRXR) and full length PXR (pCMXPXR), both under 
the control of a cytomegalovirus (CMV) promoter. The pLucPXRRE plasmid containing 
PXR response elements controlling expression of luciferase was used in the transfection. 
As seen in Figure 4.13a AMI 3 is able to activate full length of PXR with RXR with same 
fold activation as rifampicin. However, fold activation of AMI 3 is slightly lower in 
comparision to fusion of GBD:PXRLBD (Figure 4.13b). Lower activation can be due to 
different interaction of Gal4 DBD with Gal4 response element versus PXRDBD and PXR 
response elements. However, these results are promising and show that PXR/RXR 
heterodimer can be activated by AMIs. 
 In conclusion, we demonstrated novel PXR ligands based on the structure of AMI 
core. These four groups of compounds are potential PXR agonists and some of them 
display higher activation level in comparision with known PXR ligand, rifampicin. The 
most important feature of these compounds is an alkyl group that probably takes place in 
creating key hydrophobic contacts in the binding pocket. As previously reported,  
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Figure 4.13 Activation profile of heterodimer PXR with AMI 3. 
A. HEK298T cells transfected with full length of PXR and full length 
of RXR with PXR response elements, B. HEK298T cell transfected 
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most of PXR ligands are hydrophobic with logP (3.5-10) [18]. Calculation of the logP of 
PXR AMIs showed that it varies between 3.5 and 5 (Table 4.2). However, the compounds 
that do not activate this nuclear receptor displayed the logP below 3. These results 
indicate importance hydrophobicity of the AMI for the PXR activation. However, 
specific polar groups are significant to achieve enhanced activation as in case of group A 
of AMIs. Similar to that observed between logP and activation level, a correlation was 
found in the size of molecular surface and activation. Molecular surface of the best PXR 
AMI agonist has a size of 550-650 Å2 and decreases to 300-500 Å2 in the case of AMIs 
that do not activate PXR. It suggests that volume of the ligand is important to achieve 
optimal contact with residues in the ligand binding pocket. Despite that fact that PXR 
ligand binding pocket is flexible and is able to accommodate ligands of different size and 
shape, in case of AMI, molecular surface below 500 Å2 cause that activation level is 
significantly decreased.  
 
4.4 Molecular modeling of Fluophores 
 In order to determine whether, AMIs are able to activate PXR due to the specific 
hydrophobic and polar contacts or ligand shape and volume, molecular modeling of 
AMIs into ligand binding domain of PXR was performed. Modeling was performed with 
AutoDock Vina, using crystal structure of ligand binding domain of PXR with SR12813 
(PDB:1NRL) [36]. 
  Four identified classes of PXR AMIs were docked into the crystal structure of 
PXR LBD bound to SR12813 after previous removal of the ligand. This crystal structure 
was chosen based on the size of the ligand bound into PXR. As mentioned previously, 
PXR LBD is highly flexible and modeling AMI into LBD bound with large ligand such 
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as rifampicin will not give expected results. Thus AMIs were docked into crystal 
structure of PXR LBD with ligand of similar size to AMIs. As seen in Figure 4.14A the 
modeled AMI 4 into structure of LBD of PXR, binds in position of SR12813 inside of 
ligand binding pocket as other fluophores. However, the AMI 1 is located in the opposite 
orientation as seen with AMI 4 and SR12813 (Figure 4.14b). This result is not surprising, 
since AMI 1 does not activate PXR and AMI 4 is the best agonist between all tested 
fluophores. In case of others AMIs from group A, data indicates importance of length of 
alkyl chain for activation. These theoretical models show that increase number of the 
carbons in alkyl chain create significant increase of space in LBP which could create 
steric clashes (Figure 4.14c). However, too short alkyl chain can lead to a decrease in 
hydrophobic contacts of ligand with residues in LBP and this leads to lower activation. 
The experimental and theoretical data indicates that six carbon chain is optimal for 
getting the highest PXR activation.  
 To determine the importance of hydroxyl group in position R2 of AMI core in the 
class A of AMIs, we compare the modeled AMI 4 with AMI 11 which differs only by 
hydroxyl group. As seen in Figure 4.15A, AMI4 is able to create the hydrogen bond with 
serine S247, which lacks in case of AMI 11. It has been known that S247 is significant 
for interaction with SR12813 [35]. We have shown that group A which differs from 
group B only about the presence of hydroxyl group give much higher activation than 
group B. Thus this theoretical model implicated hydroxyl group to be involved in 
increasing activation level.  
 To further investigation of binding of class D of AMIs, AMI 16 was modeled into 




















































































































































































Figure 4.15 Modeling of PXR LBD crystal structure. A. Overlay of docked 
structure of AMI 4 (blue) and 11 (dark blue), B. Overlay of the docked structure 
of AMI 16 (green) with crystal structure of SR12813 (pink) 
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position as in SR12813, producing the binding energies of  -9.4 kcal/mol; the lowest 
binding energy received from modeling of AMIs. These results indicate that class D of 
AMIs is able to bind in similar manner as SR12813. It correlates to data achieved 
previously, where AMI 16 and 17 are found to activate PXR in similar level as other 
known PXR activators. 
 Knowledge gained from modeling of binding AMI into ligand binding domain of 
PXR implicates the hydrophobicity, volume and hydrogen bonding essential for 
activation. Although these theoretical models provide important highlights into 
understanding “behavior” of AMIs inside of the binding pocket of PXR, this knowledge 
needs to be carefully adapted to future designing of PXR ligands. Flexible nature of PXR 
LBD creates a challenge for molecular modeling of this nuclear receptor [19, 37-39]. 
Thus, comprehensive analysis of binding and activation of PXR AMIs will be essential 
for developing novel classes of PXR agonists. 
   
4.5 Visualization of PXR in mammalian cells using Fluophores 
 The goal of this work is development a novel PXR agonists, which will be able to 
“turn on” fluorescence in the presence of the PXR. As discussed in Chapter 2, AMIs that 
acts as agonist, are hypothesized to bind to the LBP of nuclear receptors by mimicking 
the effects of the β-barrel and restore the fluorescence by rigidifying the flexible 
fluophore.   
 In order to determine whether PXR AMIs are not only able to act as agonists but 
also display fluorescence upon binding, AMIs were tested for fluorescence using 











































Figure 4.16 Confocal microscopy with AMI 3. NIH3T3 cells incubated 
with AMI 3, A. and B. NIH3T3 cells without expressed PXR, C. and D. 
NIH3T3 cells transformed with PXR/RXR, C. and D. Cells image with 





Figure 4.17 Confocal microscopy with AMI 4. NIH3T3 cells incubated 
with AMI 4, A. and B. NIH3T3 cells without expressed PXR, C. and D. 
NIH3T3 cells transformed with PXR/RXR, C. and D. Cells image with 
overlay cells in DIC. 
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and cells were incubated with10 µM of the ligand for six hours. As shown in Figure 4.17 
and 4.18, the cells in the presence of the AMI 3 and 4 and the PXR displayed localized  
fluorescence. The cells which were expressing PXR/RXR and incubated with AMI 3 did 
not display high background fluorescence in comparision to cells without the receptors. 
However, the cells expressing receptors display fluorescence localized in the nucleus. 
These finding are not surprising due to overexpression of PXR in the nucleus.  However, 
AMI 4 shows fluorescence in the cytoplasm without expression of the PXR. It means that 
AMI 4 is responsible for non specific binding in the cytoplasm of the cell. Surprisingly, 
when cells are expressing PXR/RXR heterodimer, localization of fluorescence is 
changed. Fluorescence is observed in the nucleus instead of the cytoplasm. These 
findings indicate that AMI 4 is able to bind and fluoresce upon binding to receptor. 
Probably, after binding receptor is moving to nucleus. These results are promising to 
show that AMIs are not only able to bind and active PXR but also they display 
fluorescence upon binding. Furthermore, more studies are needed to determine the 
correlations between fluorescence and activation. Some of fluophore agonists did not 
display fluorescence upon binding, when others as AMI 3 and 4 did. Comprehensive 
studies of fluorescence in vitro and in vivo and crystallography will be necessary to 
understand the correlations between fluorescence, binding and activation. These data will 




The goal of this work was developing novel PXR agonists based on 
arylmethyleneimidazolidinone (AMIs) core, which will be able to fluoresce upon 
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binding. Successfully, four classes of PXR ligands were discovered. Experimental studies 
and theoretical modeling provided insight into the correlation between structure of AMIs 
and activation level. The data implicated the importance of length of alkyl chain in R1 
position of AMI core. The six carbon chain is optimal to get the highest activation level. 
Besides hydrophobicity, the importance of hydroxyl group in R2 position of the AMI core 
was discussed. Absence of this moiety causes a significant decrease in activation. 
Additionally, we have explored the effect of the 2,6-di-tert-butylphenol moiety, main part 
of SR12813 in AMI core for activation level. Incorporation of this moiety into the AMI 
core leads to activation comparable to that of rifampicin, the known PXR agonist.  
Hence, part of the goal was to determine if these novel PXR agonists are able to 
“turn on“ fluorescence upon binding, AMIs were tested in NIH3T3 cells using confocal 
microscopy. We have found that AMI 3 and 4 displays fluorescence upon binding PXR 
in cells. These results show that AMIs can be potentially used as fluorescence probes to 
detect PXR cell trafficking. However, more extensive studies need to be done to 
understand complexity of correlation between binding, activation and fluorescence of 
these ligands. This knowledge will be necessary to develop more sensitive PXR ligands 
with enhanced fluorescence upon binding to the receptor. 
 
4.7 Materials and Methods 
 
Ligands 
Rifampicin (MW=823 g/mol) was purchased from Sigma (St. Louis, MO).  
Compounds were synthesized by Dr. Anthony Baldridge. Synthesis of AMI compounds 
1-7, 9 was carried out by a 2+3 cycloaddition of the corresponding aromatic Schiff base 
 104 
with the imine ester as described in Chapter 2.  Schiff bases were prepared by reaction of 
the aromatic aldehyde (1eq) with the corresponding primary alkyl amine (1eq) according 
to the literature.  The imine ester was prepared according to literature. Compound 8 was 
prepared using the corresponding aromatic aldehyde (1eq), aminobutanoic acid (1eq), and 
sodium hydroxide (1eq). 
 10 mM stocks of each ligand were dissolved in80% ethanol: 20% DMSO and 
stored at 4 °C.  
 
Transfection in 3T3 cells 
HEK293T cells (ATCC, USA) were transfected with the plasmid 
pCMXPXRLBD.  This plasmid contains the Gal4DBD (GBD) fused to the wild-type 
PXR ligand binding domain LBD (GBD:LBD fusion under the control of a 
cytomegalovirus (CMV) promoter).  The reporter plasmid, p17*4TATAluc, contained the 
Renilla luciferase gene under the control of four Gal4 response elements located 
upstream from a minimal thymidine kinase promoter. The pCMXβgal, a plasmid 
containing the β-galactosidase gene under the control of the mammalian CMV promoter, 
was also used as an internal standard. Lipofectamine 2000 (Invitrogen, USA) was used as 
the cationic lipid. Ligands were added to the wells at various concentrations.  Cells were 
harvested and analyzed for luciferase and β-galactosidase activity.  All data points 
represent the average of triplicate experiments normalized against β-galactosidase 
activity.   
 
In silico Docking Studies 




 Confocal microscopy were performed as described in Chapter 3 
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CHAPTER 5 
FLUOROPHORES AS LIGANDS FOR THE RETINOIC ACID 
RECEPTOR ALPHA 
5.1 Retinoic Acid Receptor α ( RARα) 
 
 Retinoids are a class of polyisoprenoids that are the natural or synthetic 
derivatives of vitamin A [1, 2]. These small molecules are significant for embryonic 
development and play essential role in physiological functions, such as differentiation, 
homeostasis, cell growth, carcinogenesis and apoptosis[3, 4]. Their function is linked to 
the binding to retinoic acid receptors (RARs) and retinoid x receptors (RXRs). These 
receptors are members of steroid/thyroid hormone nuclear receptor superfamily and 
function as ligand dependent transcription factors involved in regulating gene networks 
that control cell growth, differentiation and death. As a member superfamily of nuclear 
receptors, RAR is a ligand dependent transcription factor with common structure to all 
nuclear receptors, including N-terminal activation function AF-1, DNA binding domain 
DBD and C-terminal ligand binding domain LBD (Figure 5.1) [5]. The natural ligand of 
RAR is all-trans retinoic acid (ATRA). RAR and RXR form non – permissive 
heterodimers, which need RXR ligand 9 - cis retinoic acid to respond to RAR’s ligands  
[6]. A number of synthetic ligands are used as therapeutic agents for many RAR-related 
diseases, such as tazarotene, AGN195183, R667 and tretinoin (Figure 5.2) [7]. However, 
some retinoids that are pan-specific for all RAR isotypes, are also toxic, as in the case of 
ATRA. This ligand is a successful drug for acute promyelocytic leukemia (APL), but also 






































































































All-trans retinoic acid AGN 195183 
R667 Tazarotene 
Bexarotene LGD 1550 
Figure 5.2 RAR ligands which are approved for therapy. 
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RAR isotype-selective modulators are essential for developing therapeutics with 
decreased number of significant side effects. 
  Retinoic acid receptor has three isotypes known as α, β and γ [10-12]. They are 
encoded by separate, highly conserved genes, resulting in each isotypehaving a unique 
function [8]. RARα is predominatnly involved in skin differentiation, hence its 
involvement in acute promyelocytic leukemia (APL) by unregulated differentiation of 
leukemic cells [13, 14]. RARβ is responsible for embryogenesis and is also known as a 
suppressor of growth of different cell types and is silenced in various cancers [15]. On the 
other hand, RARγ is implicated in many skin diseases such as a skin cancer, acne and 
also in photoaging [16-18]. 
 The ligand binding pocket of all RAR isotypes is predominantly hydrophobic. 
The hydrophobic ring of the retinoid is accommodated inside the ligand binding pocket in 
such way to create contacts with helix 11. However, the other side of the retinoid which 
contains polar groups interacts with helix 3 and helix 5. The RAR isotypes differ about 
51 amino acids in the LBD [19].  However, these isotypes differ in only about three 
residues in ligand binding pocket. RARα and RARβ diverge by only one residue in helix 
3 (S232 in RARα, A225 in RARβ). However, RARβ and RARγ differ by two residues, 
one in helix 5 (I263 in RARβ, M272 in RARγ) and other in helix 11 (V398 in RARβ, 
A397 in RARγ) [19-21]. As with most nuclear receptors, there is a lack of a deeper 
understanding of the mobility and trafficking of these receptors.  Specific questions 
regarding the mobility of these receptors within the cell still exist, especially in relation to 
their function as transcription factors.  Furthermore, understanding the trafficking of 
these receptors upon binding of agonist or antagonists, and on a time dependent scale can 
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provide insight into the natural function of these proteins, as well as their role in the 
various diseases.  Using techniques, such as fluorescence, can be used as powerful tools 
for investigating RAR function in vivo.  In particular, fluorescent probes were reported 
based on the hydrophobic ring of the retinoid ligand and a fluorescent dansyl moiety 
(tetrahydrotetramethylnaphatalenyl). These probes were designed to bind RARα and 
display fluorescence.  As shown in Figure 5.3, these designed compounds DAM-3, 
ADAM-3 and DAM-15 were built based on the core of known RARα ligands AM580 
and AM80, where binding studies were shown that these compounds were able to bind to  
the receptor. The use of the tetrahydrotetramethylnaphatalenyl moiety allowed for these 
probes to have a high binding affinity for the receptor. However, the dansyl moiety, 
which is responsible for the fluorescence, is bulky and is positioned outside of the ligand 
binding pocket. The location of this moiety on the surface of the protein could influence 
the natural function of these receptors and their interactions with other transcription 
factors.  Activation profiles on these compounds were not reported, and this is most likely 
due to the fact that the bulky nature of the dansyl moiety and its location on the surface of 
the protein, disrupted the natural function of these receptors and prevented the specific 
interactions with coactivators and other transcriptional regulators. Due to their 
implications in several diseases, and the success of both RAR agonists and antagonists as 
therapeutics towards these various diseases, discovering potential new ligands for these 
receptors are greatly beneficial. In addition to discovering a potential new class of ligands 
for these receptors, if these molecules have the ability to fluoresce upon binding to the 
receptor, they could serve as potential probes for analyzing the mobility of RAR in cells. 




Figure 5.3 Structure of the fluorescent probes for RARα. 
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will be able to exhibit fluorescence upon the binding to the receptor.  As previously 
described in Chapter 3 and 4, the goal of this work is development of fluophores based on 
the arylmethyleneimidazolodinone (AMI), the GFP chromophore for various nuclear 
receptors. 
 
5.2 Fluophores Design for RARα 
 Analysis of known RARα ligands and properties of the ligand binding pocket of 
this receptor led us to design the RARα ligands based on AMI core. Incorporation of 
known retinoid moiety into AMI core could provide an opportunity to develop novel 
RARα agonists which will bind and activate the receptor and also fluoresce upon binding. 
Thus, our design of RARα AMI was subjected to molecular modeling to determine 
possible interactions of AMI with LBP. 
 
5.2.1 Molecular Modeling of Designed RARα AMI 
 To determine if AMIs were a potential class of ligands for RARα, the core AMI 
molecule was modeled into the crystal structure of RARα LBD using modeling program 
Autodock Vina. As shown in Figure 5.4B, AMI-1 was modeled inside the ligand binding 
pocket. However, upon superimposition with the ligands of the solved crystal structures, 
DAM-3 or all-trans retinoic acid, the AMI derivatives did not occupy the entire volume 
in comparison to those ligands.  In particular, the hydrophobic part of the RARα pocket 
seemed void, perhaps eliminating the hydrophobic contacts necessary for the 
receptor/ligand interactions. Structural studies of known RARα ligands, had previously 
shown that these hydrophobic contacts, especially the hydrophobic ring system of the 
ligands with helix 11, were critical for agonistic function, hence why most RAR agonists  
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Figure 5.4 Modeling of RARα LBD crystal structure with the DAM-3 and AMIs. 
A Docked structure of DAM-3, represented in space filling, B. Docked structure of 




are designed based on tetrahydrotetramethylnaphatalenyl moiety, which is able to fill the 
hydrophobic part of the pocket. In addition to the hydrophobic contacts, several hydrogen 
bonds are present that need to be maintained to fill the requirement as a RAR ligand. The 
hydrogen bonds exist between a few residues in the end of the ligand binding pocket, 
close to the surface of the protein and carboxylate moiety of the ligand. It has been 
previously shown that a water molecule and the side chains of arginine R278 and serine 
S289 create a hydrogen bonding network with the carboxylate moiety of the ligand [22, 
23]. Based on this knowledge, an AMI derivative (AMI-2) was designed to incorporate 
tetrahydrotetramethylnaphatalenyl moiety as part of its core and carboxylic acid on the 
alkyl chain to create interaction with polar residues in the end of the pocket (Figure 5.5).  
 AMI-2 was modeled into the RARα ligand binding pocket and as shown in Figure 
5.4C a similar conformation is observed with this AMI derivative and other known RAR 
ligands. The hydrophobic part of the pocket is able to accommodate the 
tetrahydrotetramethylnaphatalenyl moiety of new AMI (AMI-2) in similar manner as 
DAM-3. The modeling data also suggested that the designed AMI-2 is able to create 
hydrogen bonding with R278 and S289 by carboxylate group in R1 position of AMI core 
(Figure 5.6). These results indicated that AMI-2 should be able to bind RARα. To 
validate this theoretical study, AMI-2 was synthesized using method described previously 
in Chapter 2.   
 
5.2.2 Evaluation of Designed RARα AMI in Chemical Complementation 
 With the same methodology that was described previously for hERα and PXR, 
AMI-2 was tested for activation with RAR, first in yeast. Chemical complementation was 





















































Figure 5.6 Modeling of RAR LBD crystal structure with the 
AMI-2.  
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pGAD10BAACTR containing GAD10AD fused to coactivator ACTR were co-
transformed into the PJ69-4A yeast strain. Liquid quantitation assays of chemical 
complementation was used for testing activation profile of novel AMI as previously was 
it described in Chapter 3. In 96 well plate, yeast expressing RARα were growing in 
adenine selective media without the ligand as well as with varying concentration of the 
AMI.As a positive control, the Gal4, ligand independent yeast transcription factor was 
used. Yeast expressing RARα were also tested with its natural ligand ATRA to validate 
the assay. After 48 h incubation at 30°C, the yeast ligand activated growth which is 
linked to activation RARα was detected by reading optical density at wavelength 630 nm.  
 As expected, the yeast with Gal4 displayed growth in selective media with and 
without the ligand. The ligand activated growth was observed with ATRA as seen in 
Figure 5.7.When the AMI was tested for activation with RAR, no ligand activated growth 
was observed. This result was quite surprising due to the fact that the modeling of the 
AMI into the binding pocket seemed promising. However, the modeling presents only 
theoretical position of ligand in the pocket and this representation maybe not be accurate. 
This AMI could indeed activate the other isotypes of RAR, beta or gamma, since these 
isotypes do slightly vary in their ligand preferences.  
  
5.3 Screening of Library of Fluophores using chemical complementation 
 As previously mentioned in Chapter 3 and 4 several specific AMIs were identified 
to activate ERα and PXR. Besides activation these novel compounds were able to display 
fluorescence upon binding receptor. The same library of AMI derivatives was tested for 
activation with RARα, in the chemical complementation;liquid assay was used. Yeast  
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Figure 5.7 Activation profile of RARα with designed AMI-2. 
ATRA and Gal4 are used as positive controls. 
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expressing RARα were tested with library of AMI including 10 µM of 95 ligands and 
with its natural ligand, ATRA. The 96 well plates, with the PJ69-4A yeast strain 
expressing nuclear receptor and coactivator were incubated at 30 °C by 48h.  
 Of the 95 compounds tested, four showed ligand activation growth. AMI 42, 85 
and 109, as well as all-trans retinoic acid displayed 17 fold activation,. However, AMI 
100 showed slightly lower response with 14 fold activation (Figure 5.8). Figure 5.9 
presents the structure of four AMIs, potentially novel class of RAR agonists. Three of 
four ligands share similar structure. They have incorporated a biphenyl moiety in the 
AMI core. These initial results were surprising due to the lack of the 
tetrahydrotetramethylnaphatalenyl moiety, which is normally present in many RAR 
ligands and is responsible for creating hydrophobic contacts in ligand binding pocket. 
However, AMI 42 displays totally different structure from other 3 ligands. To evaluate 
the interactions of these compounds with RARα, AMIs were subjected to further testing.  
 Overall, the screening of AMI library using chemical complementation assay in 
yeast led to discovery of the few RARα ligands. 
 
5.4. Evaluation of Fluophores interactions with RARα in yeast 
 To determine the sensitivity of these compounds for the receptor, a dose response 
assay was performed in yeast. The ligands were tested with RARα at varying ligand 
concentrations, ranging from 1 nM to 10 µM. As a control, ATRA was used also at 
varying concentrations.   
 As expected ATRA, the natural ligand of RAR showed activation in all tested 
concentrations. As shown in Figure 5.10 three AMI compounds displayed activation with 
RARα, as seen with AMI 100 and 109 at 100 nM with EC50 200 and 350 nM,  
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Figure 5.8 Nuclear receptor screening using chemical  
complementation in yeast. Library of 95 AMIs was tested with 
 yeast expressing RARα 
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respectively based on growth with a relatively similar fold activation. AMI 85 showed 
decreased  sensitivity in comparison to AMI 100 and 109 with an ~EC50 >10 µM. AMI 
42 did not display ligand activation growth.  
 In looking at the structure of these molecules, the lack of activation observed with 
AMI-42 was not surprising due to the differences in the structure of this AMI derivative 
in comparison to the other compounds. However, the remaining three compounds that 
showed activation with RARα, all have a similar structure, incorporating a biphenyl 
group into AMI core. In doing a literature analysis, there had been reports were ligands 
based on the alkylbiphenyls has been reported to activate RARα [24, 25]. Specifically, 
novel RARβ agonists that were designed based on the biphenyl groups were reported. 
Derivatives of the 4’octyl-4-biphenylcarboxylic acid were synthesized with different 
length of the alkyl chain [24, 25]. The number of the carbons in the alkyls chain had been 
shown to have influence on activation level. Increasing length of alkyl chain showed 
increased in transcriptional activity. There is possibility that AMIs are able to activate 
RARα due to the presence of biphenyl. Based on hydrophobicity of the ligand binding 
pocket, probably incorporated to AMI biphenyl with alkyl chain is able to create 
hydrophobic contacts in the LBP. 
 The same trend and observations were present with these AMIs. In the case of 
AMI 85, in which the replacement of the alkylbenzene group with an alkoxybenzene 
group, a decrease in sensitivity was observed. This is expected due to the increased 
hydrophobicity of the phenyl groups, confirming the importance of the hydrophobic 
nature of compounds that are desgined as agonists for the RARs. In addition to the 













































Figure 5.9 Structures of potential AMI agonist for RARα 
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Figure 5.10 Activation Profile of RARα AMIs in yeast 
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with five carbons in its alkyl group displayed a higher sensitivity in comparison to 
chromophore 100 with eight carbons in this position.  
 To further analyze the importance of the number of carbons in the alkyl group and 
correlating this relationship with activation, several additional RARα agonists with 
shorter alkyl chains were designed and synthesized.  Based on the previous results 
(Figure 5.10) which indicated that the highest ligand activated growth was displayed with 
a pentyl chain (AMI 109) and that increasing the number of the carbons decreased 
activation level, the upper end of the range had been determined to be five carbons.  
However, the lower end of the range was yet to be determined, as well as whether an 
alkyl chain even needed to be present in order to get any activation.  Therefore, AMI 129 
with a propyl group was synthesized and AMI 153 which lacked an alkyl chain was also 
synthesized. The question of the hydrophobicity was also evaluated, where the 
hydrophobicity was increased with AMI 92 where a twelve carbon alkoxyl chain was 
synthesized (Table 5.1). These compounds were then tested in yeast once again using the  
liquid quantitation assay of chemical complementation as described previously.  
  As shown in Figure 5.11 novel ligands for RARα were not able to display higher 
activation than AMI 109 (EC50= 220 nM) . Several conclusions were made. First 
decreasing the number of carbons of the alkyl chain perhaps failed to create sufficient 
contacts with the residues in the pocket. AMI 129 containing propyl group has EC50 of 
160 nM in comparism to AMI 100 (EC50= 280 nM) with octyl chain indicating that the 
presence of the alkyl group is necessary for sensitivity with the receptor. This was further 
confirmed when AMI 153 was tested, and the lack of the alkyl group in this compound 
































































Table 5.1 Structures of the RARα AMI agonists 
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derviatives.  These results indicate that pentyl chain seems to provide the ideal 
interactions that are necessary from the group of compounds that have been synthesized.  
The hydrophobic nature of the compounds seems to once again play a profound role in 
the sensitivity that is observed.  AMI 92 (EC50= 3 µM), which contains the twelve carbon 
alkoxyl chain, shows comparable activation to AMI 153 (EC50= 3 µM), but these 
compounds show reduced activation in comparison the the compounds containing the 
alkyl chains.  Therefore, the decrease in activation by introducing a polar group to the 
end of the alkyl chain reduces the hydrophobic nature of these compounds as expected.   
 
5.5 Molecular Modeling of Fluophores 
 To gain further insight into the differences in the contacts that are created between 
the receptor and these derivatives, the AMIs were docked into the  ligand binding pocket 
of RARα using AutoDock Vina. The crystal structure of the RARα LBD with BMS961 
was used  for modeling due to the similar size of the ligands (PDB:4LBD) [26]. 
The AMIs that were tested for activation in yeast were all docked and the results of the 
docking was analyzed.    
 As shown in Figure 5.12 all of the ligands were modeled into the ligand binding 
pocket and were superimposable with the BMS961 ligand. Interestingly, the alkyl chain 
superimposed directly onto the  position of the tetrahydrotetramethylnaphatalenyl moiety 
of the BMS961 ligand, which suggests that the main function of the alkyl chain is 
satisfying the necessary hydrophobic interactions in that part of the binding pocket, as 
seen in the case of the pentyl chain of AMI 109.  This could also perhaps explain why 
AMI 153, which lacks the alkyl chain, did not display any activity. It is unable to fulfill 




Figure 5.12 Modeling of RAR LBD crystal structure, BMS961 (purple) is 
used for overlay with docked structure, A. AMI 153, B. AMI 109, C. AMI 85, 
D. AMI 100 
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tetrahydrotetramethylnaphatalenyl moiety or alkyl chain as it is in case of AMIs. On the 
other hand, in the presence of an alkoxyl chain, there was a shift in the position of these 
ligands, indicating a plausible reason for the decreased sensitivity that is observed with 
the presence of the alkyoxy chain.    
 Hence, the experimental and computational data corroborate the hypothesis that 
interaction between the alkyl chain of the AMI and hydrophobic part of the ligand 
binding pocket is essential for activation. Thus, incorporation of the alkylbenzene moiety 
into AMI core can benefit in discovery novel potential RARα agonists and can replace of 
position of the tetrahydrotetramethylnaphatalenyl moiety as a major building block of the 
RAR ligand. This could provide a new structural base for developing novel RAR ligands, 
and perhaps even a new class of drugs for RAR- based disease. 
 
5.6 Visualization of RARα in yeast 
 As described in previous chapter, the part of the goal of this work was 
development of the novel ligands which will not be only potential nuclear receptor 
agonists but also will be able to fluoresce upon binding into receptor. 
 The AMIs that were tested for activation were also tested for fluroscence in yeast.   
The plasmid pGBDRARα, contained the Gal4DBD fused to the RARα LBD was co-
transformed with pGAD10BAACTR containing GAD10AD fused to coactivator ACTR 
into the PJ69-4A yeast strain. Yeast expressing RARα, were incubated in adenine 
selective media with AMI at 30 °C. After 48h of incubation, yeast were washed to 
remove any remaining media. As a control, yeast lacking the plasmid pGBDRARα were 
incubated with AMIs to detect the any background fluorescence.  
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 As shown in Figure 5.13 yeast expressing the RARα and incubated only with 
AMI 100 and 109 displayed the fluorescence. Yeast without RARα shows slight 
background fluorescence due to the known auto fluorescence that exists with yeast..An 
interesting fact that was observed is that only the AMI derivatives that contain an alkyl 
chain showed any fluorescence (AMI 100 and 109).  AMIs with alkoxyl chain did not 
display fluorescence. Again, in looking back at the modeling that was observed, this 
could perhaps conclude that for fluroscence, a certain conformation must be adopted.  
Since the conformation of the alkyoxy compounds was different in the binding pocket in 
comparison to the alkyl chains, this suggests that alkyl chain adopts the preferable 
conformation for “turning on” fluorescence. Further structural analysis, such as obtaining 
a crystal structure, needs to be obtained.   
   
5.7 Summary 
 In addition to ERα and PXR, we have discovered novel AMI agonists for RARα. 
These initial studies had shown that incorporation of biphenyl group into AMI core is 
able to create affinity of AMI to RARα. However, to enhance this activity introduction of 
the alkyl chain is necessary. The pentyl chain of AMI 109 creates significant contacts in 
hydrophobic part of the pocket. Decreasing or increasing the number of the carbons in the 
alkyl chain lead to significant undesired change in EC50. Additionally, the replacement of 
the alkyl by alkoxyl chain leads to decreasing activation.  
 Furthermore, AMI 100 and 109 displayed fluorescence in yeast, indicating that 
these molecules could indeed be fluorogens for RARα, which could provide a powerful 




















Figure 5.13 Fluorescence microscopy of RARα AMIs in yeast. Yeast 
expressing RARα (C and D) or Gal4 (A and B) were incubated with various 
AMIs. A.and C (109), B and D (100).  
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5.8 Materials and Methods 
  
Ligands 
 9-cis retinoic acid (MW=300.44 g/mol) was purchased from ICN Biomedicals 
(Aurora, OH), T0901317 (481.3 g/mol) from Cayman Chemicals (Ann Arbor, MI), 
all-trans retinoic acid (MW=300.44 g/mol) from Biomol Inc (Plymouth Meeting, 
PA),lithocholic acid from MP Biomedicals, LLC (Solon, OH). 
 The library of AMIs was synthesized by Dr. Anthony Baldridge. Method of 
synthesize was described previously in Chapter 2. 
 
Yeast transformation 
The plasmids pGBDRARα, pGBDRXRα, pGBDERα, pGBDrERβ, pGBDLXRβ, 
pGBDVDR, pGBDCAR, pGBDFXR and pGBDPPARγ and coactivator plasmids 
pGADACTR or pGADSRC-1were transformed in the PJ69-4A strain using the TRAFCO 
yeast transformation protocol. The transformation mixture was placed onto nonselective 
plates (SC-LW). Plates were incubated at 30 °C for 3 days.  
 
Liquid Quantitation Assay  
Colonies from the yeast transformation were grown overnight in nonselective media SC-
LW, at 30 °C, shaking at 300 rpm. Yeast were pelleted by centrifugation and resuspended 
in selective media SC-ALW with 10 µM or a range of ligand concentration and placed in 
96-well plates. Plates were then incubated at 30 °C, shaking at 170 rpm for 48 hours. 
After 0, 24, and 48 hours optical density readings were taken at a 630 nm wavelength. 
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In silico Docking Studies 
 Molecular modeling was performed as described in Chapter 3. 
 
Fluorescence Microscopy 
 The PJ69-4A strain expressing RARα was incubated in selective media SC-ALW 
with RARα AMIs, at 30 °C, shaking at 300 rpm. After incubation yeast were pelleted by 
centrifuging and resuspended in distill steril water. Cells were again centrifuged and 
resuspended in water. Next the cell were displayed under fluorescent microscope and 
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FLUOPHORES AS LIGANDS FOR THE RETINOID X RECEPTOR 
AND OTHER NUCLEAR RECEPTORS 
 
6.1 Retinoid X Receptor alpha  
 Besides the RAR, retinoid signaling pathway is mediating, by other retinoid 
receptors, such as the retinoid X receptor (RXR) [1]. The RXR is involved in regulation 
of organogenesis, cell proliferation and differentiation[1-3]. RXR has three subtypes, 
RXRα, β and γ which are coded by separate genes. Thus, distribution of the isotypes is 
tissue specific. RXRα is expressed dominantly in liver, skeletal muscles and skin and the 
RXRβ is found in major physiological systems. RXRγ is mainly expressed in central 
nervous system and heart [4-7]. Due to their role in various regulation pathways RXR is 
involved in many diseases such as type I diabetes, schizophrenia, autism and immune 
disorders [8-10]. 
 All RXR subtypes are activated by selective retinoids, known as rexinoids [11]. 
The endogenous ligand of RXRα is 9-cis retinoic acid (9cRA). However, there are other 
rexinoids that are known to activate RXR, such as   docosahexaenoic acid, phytanic acid 
and linoleic acid [7, 12]. Other studies have suggested that 9cRA is not natural ligand due 
to the presence other ligands in mammalian tissues. However, 9cRA is the most potent 
natural RXRα ligand with an EC50 of 1.7 nM. RXRα is also activated by many synthetic 
ligands such as targretin, LG100268 and BMS649 (Figure 6.1). 
 One of the unique functions of RXR is that it serves as heterodimer partner for 




Figure 6.1 Natural and synthetic structures of the RXRα ligands 
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(TR), the peroxisome proliferators-activated receptor (PPAR), the liver X receptor (LXR) 
and the farnesoid X receptor (FXR) [13-18]. These heterodimer partners can be non-
permissive such as VDR and TR, which their ligands are mainly responsible for 
transactivation, and that both ligands are needed for the maximal activation to be 
observed.  There are also conditionally permissive partners, in which the RXR ligand 
alone had only a minimal effect on activation and its partner's ligand enhances induced 
transactivation. They can also be permissive, in which, either the RXR ligand or the 
partner’s ligand induce the maximal activation; however when both ligands are present an 
additive approach is observed. RXR has also been shown to form homotetramers in 
cancer cells [19]. 
 The crystal structure of RXRα was the first structure of a nuclear receptor that 
was solved, revealing details of the structure of the ligand binding domain (LBD) [20]. 
More recently, the RXRα LBD in an apo (unligated) form and holo (with ligand) 
conformation has been determined. Detailed information about structure of the LBD and 
molecular recognition of ligands by RXRα was revealed. The volume of the ligand 
binding pocket was determined to be between 470 to 530 Å3 in which ~80% of the ligand 
binding pocket is occupied by the ligand [12, 21]. As with most nuclear receptors, the 
RXRα LBD consists of 12 α-helices and a β-sheet between helices H5 and H6 that are 
arranged in an anti-parallel helical sandwich, creating a hydrophobic ligand binding 
pocket (Figure 6.2) [20]. The most flexible part of the LBD is helix 12where ligand 
binding induces a conformational change in the position of helix 12, creating a binding 




























































recruitment of these coactivators eventually leads to the initiation of transcription [22, 
23].  
 Unlike steroid receptors, which upon the ligand binding translocate from 
cytoplasm to nucleus, RXR is mainly located in nucleus independently on the presence of 
the ligand [24, 25]. Recent studies have highlighted the cytoplasmic function of the RXR, 
where the role of the receptor has been extended to biological processes, such as 
apoptosis and inflammation through the cross-talking with other signal transduction 
pathways [26]. For example, RXR has been thought to take the role of in shuttling the 
orphan nuclear receptor, TR3, from nucleus to cytoplasm, allowing TR3 to interact with 
the mitochondrial protein, Bcl-2, to promote apoptosis [27]. However, more information 
regarding the expression patterns and trafficking profile of this receptor have yet to be 
determined. 
 
6.2 Evaluation of Fluophores for RXRα in Yeast and in Mammalian Cells 
 As described in previous chapters the goal of this work was development of 
fluorescent ligands which will be able to act as agonists or antagonists for various nuclear 
receptors, with the ability to fluorescence upon binding to the receptor. The successfully 
we have been able to developed AMIs for the ERα, PXR and RARα.  
 Due to the similarity between the RAR and RXR in terms of structure, the library 
of AMIs that were tested with RARα were also tested with RXR. In addition because of 
the dimerization capability of this receptor, developing an AMI, which will be able to 
bind, activate and fluoresce in the presence of the RXR, could provide opportunity 
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visualizing trafficking and molbility patterns of not only this receptor, but of other 
nuclear receptors that form partners with this receptor.   
 The library of AMI derivativeswas screened using chemical complementation 
system in yeast for evaluation of interactions of AMIs with RXRα. However, none of 
these ligands were able to induce ligand activated growth with RXRα. Based on these 
results, a library of AMIs was synthesized based on known RXRα ligands. The AMIs 
were modified based on the addition of polar groups, such as carboxyl groups which are 
present in most RXRα ligands. The shape of the ligand was taken in to account, 
accommodating the properties of the ligand binding pocket.  As result, two ligands, AMI 
S1 and S2 were chosen and analyzed (Figure 6.3). Due to their similarity in chemical 
properties and shape to the RXR ligand, 9cRA, these two compounds were expected to 
activate the receptor.  
 To gain further insight into ability of possible interaction of these ligands with 
RXRα, AMI S1 and S2 were tested using liquid quantitation assay of chemical 
complementation in yeast. As described in previous chapters, the plasmid, 
pGBDRXRαLBD, was cotransformed with coactivator plasmid pGADACTR into yeast 
strain PJ69-4A. Yeast cells containing both plasmids were placed in the 96 well plates in 
selective media (-ALW) and incubated at 30 °C for 48h. As a control, yeast expressing 
ligand independent transcription factor, Gal4, was used. As shown in Figure 6.4 ligand 
activated growth was observed with RXR and 9cRA, as expected and the Gal4 wells 
showed growth independent of ligand. However, no ligand activated growth was 
observed for RXRα in adenine selective media with AMI S1 and S2. To investigate 


















































Figure 6.3 Structures of RXRα AMIs, AMI S1 and AMI S2 based on 
the 9cRA structure. 
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Figure 6.4 Activation Profile of AMI S1 and S2 with RXRα. Gal4 
– ligand independent transcription factor, used as positive control. 
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mammalian cells, the compounds designed were tested for activation in the mammalian 
cells. HEK293T cells were transfected with a mammalian expression vector 
pCMXRXRαLBD containing the Gal4 DNA binding domain fused to the RXR ligand 
binding domain and transfected cells were incubated with the various concentration of 
AMIs and tested for activation. Using a luciferase reporter gene under the control of Gal4 
response elements, ligands AMI S1 and S2 did not display luciferase activation, whereas 
RXRα with 9cRA showed activity  (EC50= 500 nM) (Figure 6.5). These results 
conformed that AMI S1 and S2 do not activate RXRα. One of our interests was to 
determine whether these derivatives were able to bind to the receptor. These receptor - 
AMIs pairs were tested for their ability to fluoresce.  
 
6.3 Visualization of RXRα in Yeast and in Mammalian Cells 
 In order to determine if AMI S1 and S2 are able to bind and fluoresce in the 
presence of the RXRα, these compounds were tested for fluorescence in yeast. The strain 
PJ69-4A yeast was co-transformed with plasmid pGBDRXRα and pGADACTR. Yeast 
expressing RXRα, were incubated in yeast selective media with AMI at 30 °C. After 48h 
of incubation, yeast were washed to remove any remaining media. As a control, yeast 
lacking the plasmid pGBDRARα were incubated with AMIs to detect the any 
background fluorescence. To determine if interaction of the tested AMIs are specific, 
yeast expressing RXRα were incubated with AMI 2, the ERα agonist and 9cRA, the 
natural RXRα ligand.  
 As shown in Figure 6.6 yeast expressing only Gal4 and incubated with AMI S1 as 
well as with S2 did not display any fluorescence, displaying no basal fluroscence. 
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However, cell expressing RXRα fluoresce only in the presence AMI S2. On other hand, 
the yeast expressing RXRα incubated with 9cRA or AMI2, a known ERα agonist,did not  
Figure 6.5 Activation profile of RXRα with AMI S1, S2 and 9cRA 














































Gal4 RXRα / 9cRA 
RXRα / AMI 2 
 AMI S1 AMI S2 
Figure 6.6 Fluorescence microscopy of RXRα AMIs in yeast. Yeast 
expressing RXRα or Gal4 were incubated with various AMIs, AMI S1, AMI S2 




display fluorescence. These results corroborate the hypothesis that AMI S2 is able to bind 
and fluoresce in the presence of the RXRα and displayed fluorescence is specific only to 
cells which express the receptor, Therefore, although activation was not observed with 
this ligand receptor pair, the AMI derivative seems to be able to bind to the receptor, and 
upon binding, fluorescence is observed.  
            To confirm the results which were obtained in yeast, fluorescence of AMI 
S1 and S2 was evaluated in mammalian cells. The NIH3T3 cells were transfected with 
the mammalian expression vector pCMXGRXRLBD expressing Gal4DBD:RXRαLBD 
fusion protein and incubated in media with S1 and S2. To determine the amount of 
background fluorescence observed with cells and the compounds, the NIH3T3 cells 
transfected with RXRα were exposed to 9cRA and AMI2 (ERα agonist) as well as cells 
lacking RXRα were also exposed to the AMI compounds. 
 As shown in Figure 6.7 in the presence of RXRα, 9cRA and AMI2 displayed no 
fluorescence. Also cell lacking RXRα do not fluorescence after incubation with S1 or S2. 
However in the case of compound AMI S2, fluorescence was observed in the NIH3T3 
cells expressing RXRα, despite the absence of activation. Slight fluorescence was 
observed with the S1 chromophore.  The pattern of fluorescence displayed with the S1 
chromophores showed speckles of fluorescence localized around the nucleus, whereas the 
S2 chromophore displayed an intense bright light spanning the entire nuclear area. The 
most probably, S1 is not able to bind RXRα and compound is not able to be transfer to 






AMI S2 AMI S1 
Figure 6.7 Fluorescence of mammalian cells. NIH3T3 cells transfected with 
RXRα or without transfection were incubated for 24 h with AMI S1and S2, AMI 2 
and 9cRA 
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observations suggest like in case of ERα described in Chapter 3 that activation and 
fluorescence can be independent of each other.  
                            6.3.1 Evaluation of AMI interactions with RXRα 
Previously, studies had shown that water molecules present in a ligand binding 
pocket of a protein, have been shown to play a part in  modifying  the shape and 
flexibility of the binding pocket, improving the steric complementarities between the 
protein and the ligand, thus playing a significant role in the protein-ligand interactions 
[28]. This importance is based on their ability to mediate the interactions between the 
ligand and the protein by forming hydrogen bonded network that stabilizes protein-ligand 
complex [29, 30]. 
To date, there are four crystallographic structures of RXR ligand binding domain 
with bound to 9cRA, the docosahexaenoic acid (HXA), synthetic compound BMS 649 
and to 3-(2'-propoxy)-tetrahydronaphtyl cinnamic acid (3TN) [11, 12, 21]. There are 
several water molecules that are conserved in all four structures of RXR, and a water 
molecule displaced by some of the four ligands, which were identified by superimposing 
the structures of the same protein complexed with the different ligands using Relibase [31 
]. Analysis of the conserved water molecules in all four x-ray structures of RXR showed 
that there is a conserved hydrogen bond network, involving several buried water 
molecules that bridge the polar atoms of the ligand to the backbone and/or the side chain 
groups of the protein. However, the comparison of all the water-mediated interactions 
shows that some of them are common to all the structures of the RXR ligand binding 
pockets. We noticed that the carboxylate group from all the ligands participates in a 








Figure 6.8  RXRαQ275L variant. A. Water mediated interaction between 
RXR residues and 9cRA. B. Selection assay for yeast growth in presence of 
9cRA 
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network involving the backbone carbonyl group of Leu309 and the side chains of Arg371 
and Gln275 (Figure 6.8A). However, the side chain of Ser312 is also connected with 
carboxylate group of the ligand by water mediated hydrogen bond network as it is in the 
case of RXR bound to 9cRA and HXA. By using these observations we proposed to 
design a RXR mutant, which carried single mutation that could disrupt the water-
mediated interaction between the ligand and the protein. 
In order to confirm the binding of AMI in the ligand pocket of RXR and  
displayed fluorescence, due to interaction of the AMI S2 with RXRα, engineering of 
RXRα variant  could bring the insight into specific interactions between the ligand and 
the receptor.. We hypothesized that introducing specific mutations can lead to a 
disruption a water-mediated interaction between the ligand and the protein. Using site-
directed mutagenesis, residue Q275 was mutated to leucine to determine whether 
replacing polar with non polar can disturb the water mediated interaction by eliminating 
the hydrogen bonding and lead to decrease of affinity to ligand.  
The Q275L RXRα variant was transformed with coactivator plasmid into PJ69-4A yeast 
strain and tested using chemical complementation. As shown in Figure 6.8B ligand 
activated growth was observed only in case of yeast expressing wtRXR with an EC50 
value of 500 nM. As expected, RXRα variant did not display ligand activated growth 
probably due to disturbed water mediated interaction with carboxyl group of 9cRA. Thus 
we hypothesized that this variant will have also disturbed interactions with AMI S2, 
which could lead to lack of fluorescence.  Furthermore, RXRαQ275L variant was 
transformed into PJ69-4A along with coactivator plasmid. After incubation cells were 
washed and tested for fluorescence by using fluorescence microscope. As shown in  
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Gal4 RXR RXRQ275L 
Figure 6.9 Fluorescence microscopy of RXR variant . Yeast expressing, 




Figure 6.9 yeast expressing RXRαQ275L variant did not fluoresce with AMI S2 in 
compare to yeast expressing RXRα which display fluorescence. RXRαQ275L variant, 
used as a negative control. This indicated that the AMI mediated fluroscence was due to 
the binding of the AMI inside the pocket, and upon disrupting key contacts in the pocket, 
such as the hydrogen bonding network, the AMI derivative is no longer able to bind 
inside the pocket.  Thus, fluroscence is not observed.   
 
6.4 Molecular Modeling of Fluophores. 
 Molecular modeling was used to gain insight into conformation of AMIs inside 
the RXRα ligand binding domain. Thus, modeling was performed with AutoDock Vina, 
using crystal structure of the ligand binding domain of RXR with 9cRA (PDB:1FBY). 
AMI S1 and S2 were docked into the RXRαLBD. As shown in Figure 6.10 both AMIs 
are able to bind inside the ligand binding pocket. Superimposition of the AMI S1 and S2 
with 9cRA shows that these compounds are able to adopt a similar conformation to 
natural ligand of RXRα. They display the shape of 9cRA inside the ligand binding 
pocket. Based on the theoretical positions of AMIs in the ligand binding pocket is 
difficult conclude why only AMI S2 is able to “turn on” fluorescence upon binding. It is 
possible that longer chain in case of AMI S2 provides a more hydrophobic environment 
and allowing for a tighter interaction between the receptor and the ligand.   
 









Figure 6.10 Modeling of AMI S1 (A) and S2 (B) in binding pocket of RXRα  
                     with overlay of 9cRA. 
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 To determine whether library of AMI derivatives are able to activate other nuclear 
receptors, chemical complementation assay was used using a liquid quantitation assay of 
chemical complementation, allows for a quick and easy method for deciphering  
receptor/ligand interactions.  The following receptors were tested for activation with the 
AMI derivatives: rat estrogen receptor β (rERβ), vitamin D receptor (VDR), liver X 
receptor (LXRβ), retinoid X receptor α (RXR α), constitutive androstane receptor (CAR), 
Farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor γ (PPARγ). 
LXRβ, RXR, CAR, FXR and PPARγ were tested in adenine or histidine selective media. 
Due to the known leaky of expression of the HIS3 gene, 3-amino-1,2,4-triazole 3-AT (3-
AT ) the an inhibitor of imidazoleglycerol-phosphate dehydratase was used to reduce 
background. 
 Each of the nuclear receptors was tested with library of AMI including 95 ligands 
and with natural or synthetic ligand. Thus, rERβ were tested with 17-βestradiol, RXR 
with 9-cis retinoic acid, VDR with lithocholic acid and LXR with T0901317.  CAR, FXR 
and PPARγ were previously shown to be constitutively active nuclear receptors in yeast, 
where an endogenous ligand is perhaps binding to these receptors and activating them.  
This is not surprising due to similarity with the metabolites that are present in both yeast 
and mammalian systems.  However, we decided to test against the library of AMIs to 
determine whether AMIs are able to serve as potential antagonists for these receptors. 
  The 96 well plates, with the PJ69-4A yeast strain expressing nuclear receptor and 
coactivator were incubated at 30 °C by 48h. Ligand activated growth was not observed in 
case of 96 well plates with yeast expressing VDR, LXRβ, rERβ and RXR as shown in 
Figure 6.11. As expected, the plates with yeast expressing CAR, FXR and PPARγ have  
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Figure 6.11 Nuclear receptor screening using chemical  
complementation in yeast. Library of 95 AMIs was tested with 
 yeast expressing rERβ, VDR, LXRβ, RXRα. Red line shows 
expected ligand activated growth. None of the ligands show ligand 
activated growth with tested nuclear receptors. 
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showed constitutive growth. Overall, the screening of AMI library using chemical 
complementation assay in yeast did not show ligand activated growth with other nuclear 
receptors. In spite of lack of discovery novel AMIs for other nuclear receptors, these 
results indicated that AMIs which previously showed activation for ERα, PXR and RARα 
are specific for these nuclear receptors. 
 
6.6 Summary 
 As discussed in previous chapters, we discover several AMIs which besides 
displaying fluorescence in the presence of the receptors they also act as agonists for ERα, 
PXR and RARα. Here we presented the discovery of AMI S2 which is able to bind to 
RXRα and fluoresce upon binding. Discovery of this compound, which fluoresces in the 
presence of the RXRα but does not activate is extremely important because it can serve as 
potential antagonist for RXRα. However, they can also be used as a potential fluorescent 
probes for traffic this receptor in the cell. 
 On the other side these results provide opportunity for development of novel 
AMIs which will not only able to bind and fluoresce but also activate RXRα.  
 
6.7 Materials and Methods 
 
Ligands 
 9-cis retinoic acid (MW=300.44 g/mol) was purchased from ICN Biomedicals 
(Aurora, OH), all-trans retinoic acid (MW=300.44 g/mol) from Biomol Inc (Plymouth 
Meeting, PA). 
 161 
 The library of AMIs was synthesized by Dr. Anthony Baldridge. Method of 





Mutation Q273L was introduced into the yeast expression plasmid, pGBDRXRα 
by using PCR (Stratagene, Santa Clara, CA) with specific mutagenic primers (Operon, 
Huntsville, AL) and DpnI digestion. Plasmid carried mutation was purified using the 
QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA). 
 
Yeast transformation 
The plasmids pGBDRXRα and coactivator plasmids were transformed in the 
PJ69-4A strain using the TRAFCO yeast transformation protocol. The transformation 
mixture was placed onto nonselective plates (SC-LW). Plates were incubated at 30 °C for 
3 days.  
 
Liquid Quantitation Assay  
PJ69-4A expressing RXRα was grown overnight in nonselective media SC-LW, 
at 30 °C, shaking at 300 rpm. Yeast were pelleted by centrifugation and resuspended in 
selective media SC-ALW with 10 µM or a range of ligand concentration and placed in 
96-well plates. Plates were then incubated at 30 °C, shaking at 170 rpm for 48 hours. 
After 0, 24, and 48 hours optical density readings were taken at a 630 nm wavelength. 
 
In silico Docking Studies 
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 Molecular modeling was performed as described in Chapter 3. 
 
Fluorescence Microscopy 
 The PJ69-4A strain expressing RARα was incubated in selective media SC-ALW 
with RARα AMIs, at 30 °C, shaking at 300 rpm. After incubation yeast were pelleted by 
centrifuging and resuspended in distill steril water. Cells were again centrifuged and 
resuspended in water. Next the cell were displayed under fluorescent microscope and 
analyzed for green fluorescence. 
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ENGINEERING NUCLEAR RECEPTORS TOWARDS 
FLUOROPHORES 
7.1 Engineering Nuclear Receptors to bind Fluophores 
  As discussed in the previous chapters, the main goal of this work was the 
development of fluorogens to bind and activate various nuclear receptors. AMIs were 
characterized for ERα, RARα, PXR and RXRα. In most cases, the approach taken for 
discovering these novel AMIs required some modeling, and eventually the screening of 
small libraries of AMI derivatives.  However, often times there seemed to be a lack of a 
correlation between the modeling results obtained and the activation profile of these 
compounds with various nuclear receptors.  Another approach taken to gain insight into 
the structure function relationship between the AMI derivatives and nuclear receptors is 
by engineering the receptors to bind novel small molecules.  By engineering nuclear 
receptors, the opportunity to gain further insight into interaction between the ligand and 
receptor is provided. In addition to the structural information gained through this process, 
engineering receptors to bind novel small molecules can also be used in a series of 
applications, ranging from gene therapy applications to biosensors.  
             To date, engineering nuclear receptors such as RARα, RXRα and ERα have been 
reported. Some of these studies were directed towards alanine scanning mutagenesis of 
the residues inside the ligand binding pocket to investigate their specific role in ligand 
binding [1-4]. However, mutagenic studies were also focused on creating orthogonal 
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Synthetic Ligand 
Figure 7.1 Receptor – ligand orthogonal pair. Wild-type receptor is able to 
respond to natural ligand but not to synthetic ligand. Engineered receptor is 
able give response to synthetic ligand but losing affinity to natural ligand.  
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            longer is activated by natural ligand (Figure 7.1) [5-7]. These engineered receptor ligand 
pairs are used in a variety of applications, such as in molecular switches for gene therapy 
[5, 7]. All of these studies generated mutations in only the LBD of these receptors using a 
rational design approach to the types of mutations that were made, where specific 
residues were selected. For instance, RXRα variants were generated that were no longer 
activated by the wild-type ligand, 9cRA, but activated in response to a synthetic ligand 
LG335. This synthetic ligand shows minimal activity with the wild-type receptor.  The 
RXR variants receptor had four mutations, I268A, I310A, F313A, and L436F which were 
localized inside the binding pocket [8]. Using this methodology relies heavily on 
understanding the structure/function relationship between the ligand and the receptor. 
Also, by limiting the mutations to the residues in the binding pocket, very little is 
understood about the effects of the secondary residues that surround the binding pocket.  
Thus, a part of our goal was to explore the possibility to engineer a receptor to bind and 
activate in response to an AMI derivative, that the wild-type receptor had shown no 
activity with.  However, to explore the impact of the residues in the entire ligand binding 
domain, random mutagenesis was employed, which had been previously used to generate 
VDR variants [9, 10].  
 
      7.2 Random Mutagenic Approach: Error –Prone PCR Libraries for VDR, LXRα, 
RXRα and ERα 
             Initially, the VDR, LXRα, RXRα and ERα were subjected to random 
mutagenesis. The nuclear receptors were chosen based on a number of different reasons.  
Our lab had previously obtained VDR variants that were discovered through random 
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mutagenesis to show activation in response to a novel ligand, therefore this receptor was 
used.  LXR was chosen as a target due to the lack of mutagenic work that has been 
performed with this receptor.  The RXRα was used because of the fact that AMI S1 and 
S2, two of the derivatives designed for this receptor, did not show activation with the 
wild-type receptor.  Our goal was to be able to discover a variant capable of showing 
activation with these two derivatives. On the other hand, ERα was subjected to random 
mutagenesis due to previous discovery of AMIs for this receptor. Engineering of wild-
type ERα could present an opportunity to enhance activation with AMIs or discover a 
variant showing activity with other AMIs derivatives. 
Libraries of variants were subjected to selective pressure using chemical 
complementation, where variants activated by specific AMI.  To engineer these variants, 
epPCR was performed by two different approaches. The first method involved using Taq 
polymerase and modifying the conditions of the PCR reaction to enhance the error-rate.   
Concentrations of manganese (II) chloride (MnCl2) with addition of magnesium (II) 
chloride (MgCl2) replace the MgCl2 that is needed by the Taq polymerase to function. 
Replacing the magnesium with managanese, still allows for the polymerase to function, 
but not with a very high efficiency.  To modulate the affinity of the enzyme various 
concentrations of MnCl2 were used (20 – 400 µM). The second approach used an 
engineered polymerase, mutazyme, was used.  This commercial enzyme is a mutated 
polymerase, which introduces mutations more frequently than Taq polymerase and does 
not require manipulation of epPCR condition.  Each of epPCR products (insert cassettes) 
were used to create libraries of variants for each nuclear receptor.  
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 To create library, the nuclear receptor insert cassette along with background 
plasmid (eg. pGBDhERαbackground) were transformed into yeast strain PJ69-A 
containing fusion protein GAD:coactivator. The background plasmid, contain the Gal4 
DNA binding domain fused to part of NR LBD, along a random sequence introducing 
multiple STOP codons, was used to decrease appearance of wild-type nuclear receptor in 
library.  However, insert cassette contained ends complementary to the specific region of 
digested background plasmid, allowing for homologous recombination to take place 
between the insert cassette with mutations and the digested background plasmid and 
create expression plasmid containing Gal4DBD fused to nuclear receptor variant’s LBD. 
The library of variants was transformed into yeast and plated onto non-selective agar 
plates (SC-LW) lacking leucine and tryptophan to select the GAD:Coactivator plasmid  
(leucine marker) and Gal4DBD:LBD expressing  plasmid (tryptophan marker). These 
plates were also used to determine whether homologous recombination had occurred and 
to determine transformation efficiency. Yeast were also plated on selective agar plates 
(SC–ALW) lacking leucine and tryptophan, as well, as adenine or histidine, and 
containing different AMIs at concentration of 10 µM. As discussed in Chapter 3, the 
selective plates were lacking adenine or histidine due to presence of the genes ADE or 
HIS3 in PJ69-A which were involved in biosynthetic pathway of adenine or histidine 
production. Activation of this selection gene, such as the HIS3 gene, which was under 
control of Gal4 response element enables the yeast strain to grow on media lacking 
histidine in the presence of the AMI. Thus, the survival of the yeast expressing specific 
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Figure 7.2 Generation of libraries of ERα variants in yeast. The library cassette 
is transformed into PJ69-A yeast strain along with background plasmid which 
contains the homology regions with cassettes. Cassettes contain the random 
mutations which were generated by error – prone PCR. Through homologous 
recombination, library of ERα variants were created. 
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7.2.1 Results of Error-Prone Libraries 
 As shown in Table 7.1, for each receptor, a similar library size in the range of 103 
- 104 variants was obtained and transformation efficiency in range of 104 – 105 cfu/µg VC 
was observed. Despite of large number of created variants, no ligand activated variants 
were observed with the VDR, RXRα and LXR libraries. However, the ERα libraries 
resulted in several dozen potential ligand activated variants for specific AMIs. 
 Most of variants were tested for ligand activated growth by streaking out onto non 
–selective (SC-LW), selective (SC-ALW) and ligand (SC-ALW +AMI) plates. Most of 
variants display growth on selective plates SC –ALW, which indicated that they are 
constitutively active, growing without the presence of ligand. This could indicate two 
possibilities: (1) these variants are binding an endogenous ligand, or (2) that these 
variants have structural modifications that enable the active of the receptor to become 
independent of the presence of ligand. However, the most surprising aspect of this is that 
these variants did not grow on selective plates with the AMI ligands, suggesting that 
perhaps these AMI compounds are acting as antagonists, ligands that bind but do not 
activate these receptors. To determine activation the profile of the obtained variants, 
several from each library were sequenced and retransformed to yeast for further testing.  
As shown in Table 7.2 most of the sequenced variants displayed single or double 
mutations and most of the mutations were outside of the ligand binding pocket. Both the 
mutazyme and Taq libraries produced a similar mutational diversity and number of 
mutations per gene.   
  To confirm the activation profile of sequenced variants, variants were tested in 

















Table 7.1 Transformation results for VDR, LXR and ERα libraries. 
Library name Polymerase Library Size Transformation Efficiency (cfu/µg VC) 
VDR_1 taq 1.3 × 104 1.8 × 105 
VDR_2 mutazyme 4.4 × 103 4.6 × 104 
LXR_1 taq 4.0 × 103 5.5 × 104 
LXR_2 mutazyme 1.5 × 103 1.6 × 104 
ERα_1 taq 1.8 × 104 2.4 × 105 



















Table 7.2 Sequencing results for ERα libraries. 
Taq polymerase Mutazyme 
Nonselective Variants 
ER1 L372H, L508P, K520E ER1  V478A, Q498K 
ER3 W383R, L403P,Q414L   
Selective Variants 
4_9 L507F, E561stop,Y582H 4_1 D374Q, N439K,M490L,Y537S 
4_23 wtER 4_15 L320stop,V478A 
24_9 E380D 24_5 P406H,K416I 
24_12 H567L 12_9 wtER 
12_8 N348S,G442R 14_20 H373N, L462P, N519I, Y537C 
12_9 wtER 23_9 K520R  
9_8 wtER 23_31 I487V 
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natural ligand of ERα, 17-β estradiol and various AMI derivatives. As seen in Figure 7.3 
and Figure 7.4, most of the variants were constitutively active, displaying growth without 
ligand as also in the presence of the AMI and 17-β estradiol. Interestingly, one of these 
variants (23_9) has a single mutation, K520R. However, besides constitutively active 
variants, two non-functional variants were obtained.   
 Finally, besides the constitutively active and non-functional variants, one of the 
variants (24_9) obtained displayed ligand activated growth in the presence of the AMI 24 
with a 5-fold activation in comparison to 8-fold activation with 17-β estradiol. Thus, the 
engineered variant showed to be activated by AMI 24. However, this ligand showed 
previously slight growth and low sensitivity (EC50 > 10mM) with wild-type ERα.  
 
7.3 Testing E380D variant in chemical complementation 
 Variant 24_9, which contained a single point mutation at position 380 (E380D), 
showed a novel activation profile with AMI-24.  In comparison to the activity with wild-
type ER, this variant showed an increase in the fold activation from two to five fold with 
AMI 24. Due to the similarity between AMI 24 and AMI 23, which lacks two carbons in 
the alkyl chain compared to AMI 24, this ligand was also tested in yeast for activation 
with E380D variant. As shown in Figure 7.5B AMI 23 shows activation with the 
ERαE380D variant, at a relatively low activation (3-fold activation) and with an EC50> 
10 µM. ERαE380D variant enhances activation about three fold compared with wild-type 
ERα. Despite the fact that the ERαE380D variant shows activation with AMI 23 and 24, 









































Figure 7.4 Ligand activated growth profiles of ERα variants with AMI 23. 






Figure 7.5 Ligand activated growth profiles of wtERα and E380D variant. 
Receptors were tested with A. AMI 23 and 24, B.17-β Estradiol,  
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receptor (Figure 7.5A). Thus, this mutation does not have effect on binding and activation 
by 17-β estradiol. 
 Due to the ability of E380D variant to enhance activation of ERα with AMI 23 
and 24, we hypothesized that this mutation would also be able to display activation with 
other AMI derivatives which are similar in their structure to AMI 23 and 24. Thus, a 
variety of AMIs with different position of hydroxyl group on AMI core and lack of 
carboxyl group on alkyl chain of fluophore, were tested for activation E380D variant as 
well as with wild-type ERα. However, from all of the AMI derivatives that were tested, 
none of these compounds showed activation with the E380D variant or the wild-type 
receptor (Figure 7.6). This indicated that this variant did display specificity toward these 
two AMI derivatives, but others that were very similar in structure failed to activate the 
receptor. 
 
7.3.1 Influence of E380D variant on interaction with coactivators 
 To understand impact of E380D mutation on activation, the importance of this 
residue was further explored. As previously mentioned, residue E380 is localized out side 
of the ligand binding pocket and it is not in direct contact with ligand. This glutamate is 
positioned on helix 5 and pointed outward toward the solvent (Figure 7.7). Previous 
studies indicated that E380 is part of a cluster of 16 amino acid residues which create a 
binding groove for coactivators (Figure 7.8). The crystal structure of ERα with a 
coactivator peptide containing the traditional LXXLL motif of coactivator SRC-1 reveals 
a hydrophobic surface used for interaction between the coactivator and nuclear receptors. 
























































































































Figure 7.6 Ligand activated growth profiles of E380D variant. 
Part I. Engineered variant was tested with A. 17-β Estradiol, B. AMI 













































Figure 7.6 Ligand activated growth profiles of E380D variant. Part II. 















































































Figure 7.7 Crystal structure of ERα. Residue E380D is shown in 
red (pdb: 1ERE). 
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between nuclear receptor, coactivator and corepressor [13]. Changing of E380 to an 
alanine has been reported to abolish interaction with several peptides mimicking 
coactivators, and corepressors [14]. Other mutagenic work also showed that the E380Q 
variant is constitutively active. This mutation is able to modulate non-direct interactions 
with the coactivator without the presence of the ligand [15]. Furthermore, E380, the 
negatively charge residue shows conservation only within this subclass of nuclear 
receptors (Figure 7.9). As shown in Figure 7.9 alignment E380 with many nuclear 
receptors shows that glutamate is present only in case of ERα and ERβ and in other 
nuclear receptor subfamilies the positively charge lysine and arginine is present in this 
position. It the same time, other residues which together with E380 create coactivator 
binding site are conserved hydrophobic residues across all nuclear receptors. This 
indicates that perhaps the residue E380 is important for distinguishing between the 
different coactivators for the various nuclear receptors [13]. In the fact, subfamilies of 
nuclear receptors use different types of coactivators for activation. For instance, the 
steroid receptor subfamily interacts with SRC-1 class of coactivators, whereas the 
retinoid receptors preferentially bind the SRC-3 coactivators [16, 17]. 
 The presence of an amino acid residue in which the side chain is shorter by one 
carbon and that the overall charge remains the same between these residues makes the 
presence of an aspartate to a glutamate at position 380 a very conservative change.  The 
observed enhanced activation could be due to coactivator binding with a higher affinity.   
 To test this hypothesis and determine whether the presence of this mutation 
influences coactivator recruitment, chemical complementation with two different 














































Figure 7.8 Interaction of residue E380 with coactivator. A. 
Position of E380 residue with coactivator, B. Coactivator binding site 
(yellow) with E380 residue (orange) and coactivator (red). Shown in 




AR A V I Q Y S W 
ERα H L L E C A W 
ERβ R L L E S C W 
FXR A L L K G S A 
GR T L L Q Y S W 
LXRα A L L K T S A 
PPARγ T L L K Y G V 
RXRα I L L R A G W 
RARα T L L K A A C 
TRβ I L L K G C C 
VDR V L L K S S  
Figure 7.9 Sequence alignment part of Helix 5 and 6 in nuclear 
receptors. Alignment was made with selected nuclear receptors. 
Localization of residue E380 is highlighted. This residue is conserve 
between classes of NR eg. ERα and ERβ 
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coactivator-1 (SRC-1) and the activator for thyroid hormone and retinoid receptor 
(ACTR as also known as SRC-3). In addition, coactivators containing three of five 
LXXLL motifs from the SRC-1 and ACTR proteins (called SRC-1fragment, ACTR 
fragment, respectively) were tested as well. 
 As shown in Figure 7.10 the E380D variant shows a coactivator preference. 
E380D variant is activated at a concentration of 10 mM of AMI 23 and 24 in the presence 
of the SRC-1 protein and the SRC-1 fragment, which contains three LXXLL motifs. The 
SRC-1 fragment displays two-fold lower activation in compare to the full SRC-1 protein 
with both AMI 23 and 24, as well with 17β-estradiol. Influence of coactivators on E380D 
variant activation with 17β-estradiol differs from wild-type ERα. In case of wild-type 
receptor SRC-1 and SRC-1fragment coactivators has similar activation profile.  However, 
in the presence of coactivator ATCR fragment, E380D variant has increased basal 
activity and displays constitutive activity with coactivator ACTR. ACTR coactivator does 
not cause the wild-type receptor to become constitutively active as was observed with the 
E380D variant, but does increase the basal activity. 
  As mentioned previously E380 has been shown to be involved in coactivator 
binding, but has also been implicated in creating a surface for antagonistic activity.   To 
gain further insight into the importance of E380D, and the ability of the variant to 
modulate interaction with antagonists, ERα and the E380D variant were tested for 
interactions with tamoxifen and DY-001-148, known ERα antagonists and drugs against 
breast cancer (Figure 7.11). Using chemical complementation, yeast expressing E380D 
variant and wild-type receptor were incubated in the presence of the 0.1 nM 17β-estradiol 
































































































































Figure 7.10 Ligand activated growth profiles of E380D variant and wtERα with 
different coactivators A. wtERα with 17-β Estradiol, B. E380D variant with 17-β Estradiol, 






Figure 7.11 ERα antagonists. A. Tamoxifen, B. DY-001-148 
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inhibition of yeast growth by antagonists. Antagonists are able to bind and displace the 
agonist, 17-β-estradiol, preventing transcription to occur and decrease the growth 
observed as a result of agonist activity. As shown in Figure 7.12 both antagonists were 
able to displace 17β-estradiol and decrease estradiol induced growth in 10 µM of 
antagonist in case of wild-type estrogen receptor. However, in case of E380D variant 
only, compound DY-001-148 was able to act as an antagonist. Tamoxifen was not able to 
displace 17β-estradiol and inhibit ligand activated growth. These results indicate that 
probably this mutation influences the interaction with coactivators and corepressors, thus 
it can enhance activation with AMIs as well as modulate interactions with antagonists. 
 
7.4 Testing E380D variant in mammalian cells 
 To verify whether the E380D variant displays the same activation level in yeast as 
in mammalian cells, variant containing Gal4DBDfused to ERαLBD was cloned into 
mammalian expression plasmid pCMX which has CMV promoter. The constructed 
plasmid was cotrasfected into HEK298T cells with plasmid containing Gal4 response 
elements controlling luciferase expression.  
 Interestingly, E380D variant did not display a similar activation profile with AMI 
23 and 24 in mammalian cells as it has been shown in yeast. As shown in Figure 7.13 the 
tested variant does not display significant activation level compared to wild-type 
receptor. As previously described in Chapter 3 the AMI 23 and 24 activate the wild-type 
ERα with EC50 > 3 µM. Based on the yeast data, we hypothesized that E380D variant 
will be able to enhance the activation of ERα with AMIs. However, these results show 
that the introduced mutation decreased activation with AMIs as well 17β-estradiol, 
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Figure 7.12 Inhibition of estrogen receptor alpha by A. Tamoxifen, B. 
DY-001-148. Cells were incubated with 0.1 nM of 17-β estradiol and range 












































Figure 7.13 Activation profile of E380D variant in mammalian cells. 
Cells expressing wtERα or E380D variant were incubated with A. 17β-








0.0 9.0 8.0 7.0 6.5 6.0 5.5 5.0













0.0 9.0 8.0 7.0 6.5 6.0 5.5 5.0




                  - log [E2] (M) 
A 
 191 
in mammalian cells. Different expression pattern of coactivators in mammalian cells than 
in yeast could be responsible for discrepancy between yeast and mammalian data.  
  
7.5 Influence of E380D mutation on Fluophores Fluorescence.  
 To determine whether E380D mutation of ERα was able to adopt a conformation 
optimal for fluorescence after binding the AMIs, the E380D variant and wild-type ERα 
were transformed into yeast. Yeast expressing the variant and wild-type receptor were 
incubated in yeast selective media with 10 µM AMI. To determine the amount of 
background fluorescence observed with cells and the compounds, various negative 
controls were employed. First, yeast transformed with ERα were exposed to the ligands 
or to estradiol alone, and as a control, were not exposed to any of the AMI derivatives to 
check for the basal fluorescence. Also, to determine the background fluorescence due to 
non-specific binding of the fluorophore to endogenous proteins, cells lacking ERα were 
exposed to the AMI compounds. 
 As shown in Figure 7.14 slight basal fluorescence was observed in the case of 
yeast expressing ERα and incubated with estradiol. However, yeast expressing Gal4 and 
incubated with AMI 23 did not display any fluorescence. It indicates lack of background 
fluorescence that could be due to AMI non-specific interactions with other proteins in 
cell. E380D variant that was incubated with AMI 23, displayed fluorescence in yeast. 
However, wild-type ERα showed a lack of fluorescence with this ligand. Another ligand 
which actives the receptor, AMI 24, indicated similar fluorescence level in E380D variant 
















Figure 7.14 Fluorescence studies of wtERα and E380D variant in yeast. 
Yeast expressing wtERα or E380D were incubated with AMI 23 and 24. 
Yeast with Gal4 and expressed wtERα incubated with E2 were used as a 
negative control.  
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 The fluorescence data provided surprising insights into the influence of this 
mutation on fluorescence. Looking at the position of E380D in the LBD, the presence of 
the fluorescence upon binding is probably related to the interaction of this residue with 
coactivator. Interaction of ERα variant with coactivator perhaps allows for 
conformational change of AMI to turn on fluorescence. These results open new avenues 
for engineering nuclear receptors which will be able to turn on fluorescence of AMIs 
upon binding. Extensive mutagenic studies could potentially help to understand what 
interactions between protein and ligand are important to enhance ligand fluorescence. 
The gained knowledge could be applied towards development of novel fluophores. 
To determine whether results obtained in yeast with E380D variant were 
consistent in mammalian cells, an expression mammalian plasmid caring the E380D 
variant was transfected into NIH3T3 cells and HEK298T cells. Cells expressing wild-
type ERα or E380D variant were incubated with AMI 23 and 24 and tested for 
fluorescence using confocal microscopy. To detect any basal fluorescence from AMIs, 
cells not expressing ERα were incubated with AMIs as well. As expected, cells did not 
present significant basal fluorescence (Figure 7.15 and Figure 7.16). Cells containing 
ERα and E380D variant displayed fluorescence which seems to be localized in the 
nucleus of the cells. This finding is consistent with the known localization of the ligand 
after ligand binding.  
 The fluorescence data which has been obtained in mammalian cells showed that 
this E380D variant is able to enhance fluorescence. However, due to lack of activation of 
this variant by AMIs in mammalian cells questions if fluorescence visible  
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3T3 3T3 
ERαE380D wtERα wtERα 
AMI 23 AMI 23 AMI 24 
3T3 3T3 3T3 no ligand 
Figure 7.15 Fluorescence studies of wtERα and E380D variant in 
mammalian cells NIH3T3. Cells expressing wtERα or E380D were incubated 












































Figure 7.16 Fluorescence studies of wtERα and E380D variant in 
mammalian cells HEK298T. Cells expressing wtERα (A, B) or E380D (C, D) 





in the nucleus is actually linked to activation. These results indicated that AMI 23 is able 
to bind and activate E380D variant in yeast but does not display activation in mammalian 
cells.  
Perhaps, AMI 23 is able to bind E380D variant which is transferred to the nucleus 
upon binding. However, possible distracted interaction of variant with coactivator does 
not allow for activation but allows for displaying fluorescence. These findings could 
provide insight into correlations between binding, activation and fluorescence and also 
open new avenues for engineering nuclear receptors to active and enhance fluorescence 
by novel ligands. 
7.6 Extensive Engineering of Estrogen Receptor α 
 The first attempt to create an ERα library resulted in the E380D variant which 
was able to enhance activity with AMI in yeast. This discovery led us to explore whether 
the power of selection in chemical complementation will be able to receive more 
engineered variants able to be activated by various AMIs. Thus random mutagenesis by 
error-prone PCR was used to generate ERα libraries. However, as mentioned previously 
error-prone PCR required the use of Taq polymerase. To generate specific mutation rates, 
a range of MnCl2 (20 – 400 μM) was used to amplify the ERαLBD gene. The created 
insert cassettes were transformed into PJ69-A yeast strain along with digested 
background plasmid pGBDERαbackground and plasmid expressing coactivator 
pGBDSRC-1 and plated on non-selective plates (-LW) and selective plates with 10 µM of 
ligand. After 4 days of incubation at 30 °C a library of size 2 ˣ 104 was obtained. 100 
colonies were picked, retransformed and tested for constitutive activity by streaking on 
adenine selective and non-selective plates. Most streaking variants were constitutively 
 197 
active. However, a few did not grow on adenine selective plates and they were selected 
for further testing in liquid quantitation assays.  
 Variants were tested for ligand activated growth with various AMIs which were 
used for creating libraries. None of these variants displayed ligand activated growth with 
AMIs but they were functional variants as determined by activation with estradiol. 
Interestingly, one of these variants ER32 which had five mutations (T347A, F367Y, 
R436R, L489M, L504P, and L541M) displayed ligand activated growth at 100 nM with 
estradiol (Figure 7.17). This variant was not activated by AMIs but its decreased 
sensitivity towards 17β-estradiol makes it as a potential variant to engineer orthogonal 
ligand – receptor pair.  
7.6.1 Creating Second Generation ERα Variants. 
 To increase sensitivity of the E380D variant, it was used as a template for further 
engineering using random mutagenesis. In addition, to obtain orthogonal receptor, the 
ER32 variant was also subjected to engineer to obtain activity with AMIs and further lose 
affinity to 17β-estradiol. Thus, both variants were used as templates for error-prone PCR 
and, as described above, the insert cassette which obtained by PCR and transformed into 
PJ69-A along with background plasmid and plated on non-selective and selective plates. 
Additionally, a library based on wild-type ERα was also generated. 100 variants were 
picked and tested for constitutive activity. 13 variants which did not display constitutive 
activity have been sequenced and selected for further testing in liquid quantitation assays 
(Table 7.3). Variants were tested for ligand activated growth with AMI 23 and estradiol. 
Interestingly, variant NCC4 which is a first generation of wild-type ERα displayed ligand 


















































- log [ligand] (M)
ER32 with E2
ER32 with AMI 24
wtERα with E2
wtERα with AMI 24
Figure 7.17 Ligand activated growth of wtERα and ER32 variant. 
Engineered ER32 variant were tested with 17-β Estradiol and AMI 24.To 
compare activation profile, wtERα was tested as well. 
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Table 7.3 Sequencing result for second generation of ERα variants. 
 
  
 Template Mutations 
NCC1 E380D NCC7 
NCC2 wtER S338R, G366D, M396V, A405S, C457W, D473E, V533E, D545Y 
NCC3 wtER wtER 
NCC4 wtER 
 




F404F, M437L, Q441R, K449I, Y521C 
 
NCC6 E380D L310V, V364A, H377Y, M396I, A405A, H488Del, L454Del 
NCC7 E380D 
 




Q314P, N407S, I487I 
 
NCC10 E380D E380D 



























































- log [ligand] (M)
NCC4 with AMI 23
NCC4 with E2
Figure 7.18 Ligand activated growth of NCC4 variant. Engineered variant 
were tested with 17-β Estradiol and AMI 23. 
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growth with AMI 23 as well as estradiol have high basal. Two mutations of NCC4, 
M396R and M437L may have allowed for conformational change of ERα to be activated 
by AMI 23. However, this conformational change makes the variant be in partly active 
state resulting in constitutive activity.  
Library of second generation of variants did not create any variants activated by 
AMI. However, some of the second generation of ER 32 variants displayed decreased 
sensitivity toward 17β-estradiol compare to ER32. Variant NCC14, which has an 
additional mutation (Q375R) than the five mutations of ER32, shows ligand activated 
growth with 17β-estradiol at 10 µM, thus decreasing about 100 folds in sensitivity 
(Figure 7.19). Surprisingly, the NCC7 variant which is a second generation of E380D 
variant, displayed the same activation profile as NCC14. This variant, having an 
additional five mutations (E380D S329Y, L384P, F404L, I451T, and L489R) showed 
ligand activated growth with 17β-estradiol at 10 µM. However, these mutations inhibited 
activation with AMI 23, as was obtained with the E380D variant. These results indicated 
that additional five mutations to E380D restrained activation with AMI and decreased 
sensitivity towards estradiol due to perhaps their influence on folding of protein which 
does not allowed for proper interaction with coactivators and then activation.  
 Unfortunately, none of the second generation variants were the orthogonal 
variants are able to bind AMI but not to 17β-estradiol. Only one variant NCC4, was able 
to be activated with AMI 23 but it has high basal which makes it a potential engineered 
receptor with novel function. 




















Figure 7.19 Ligand activated growth of variants with decreased 
response on 17β - estradiol. Engineered variants, NCC7 and NCC14 were 
tested with 17-β Estradiol. To compare activation profiles of tested 
variants, ligand activated growth of ER32 and wtERα. 
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  An attempt to create a variant which capable of being activated by AMI required 
that we create another range of variants. The sixteen variants which were obtained from 
the previous libraries as a first or second generation of variants were used a template for 
next round of error-prone PCR. The 120 ng of each cassette obtained by error – prone 
PCR was transformed into PJ69-A yeast strain along with ERα background plasmid. 
After four days of incubations, a transformation efficiency of 5.2 x 104 was obtained, 
creating library size of about 5.5 x 103. One hundred of the variants were tested for 
constitutive activity by streaking out on selective and nonselective agar plates as 
mentioned previously. 30% of the tested variants did not display constitutive activity and 
their activation profile was tested using liquid quantitation assays with 17β-estradiol and 
a mix of eight derivatives of AMIs at 10 µM which were used as a selective pressure to 
drive the libraries. As shown in Figure 7.20 most of the variants displayed ligand 
activated growth with 17β-estradiol. However, several of variants showed ligand 
activated growth with AMIs 10 µM. All of the 16 assayed variants were sequenced and 
tested with each one of eight AMIs to find which AMIs was able to activate variants 
(Figure 7.21). Interestingly, sequencing results showed a high diversity (Table 7.4). 
Obtained variants were the next generations of the E380D, ER32, 12_8, NCC5, 24_5 and 
NCC13 variants. Additional mutations generated variants with new functions. The 
ER8GFP11 and ERL19 variants showed ligand activated growth with AMI 73 and 81. 
AMI 81 with ER8GFP11 variant had 6 fold activation versus 5 fold activation with 
ERL19. The other AMI that activates only ER8GFP11 is AMI 73 with 4 fold activation. 
These results are surprising due to the structures of the AMIs. AMI 73 and 81 differ 
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significantly in structure. AMI 73 has a similar structure to AMI 23 and 24, ERα 





























































































































Figure 7.20 Ligand activated growth of second and third generation 
variants. Engineered variants were tested with A. 17-β Estradiol, and B. AMIs. 
















 Template Mutations Activation 
ER8GFP5 E380D E380D, L384P, G442R, L525L, L579stop C.A. 
ERLW95 NCC5 E380D, F404F, M437L, K449I, Y521C, L319M EST 
ER8GFP19 12_8 N348S, G442R, L387L K302K EST, 10-5 GFP 
ERres20 12_8 N348S, G422R EST, 10-5 GFP 
ERLW3 ER32 T347A, F367Y, R436R, L489M, L504P,L541M L509P NA 
ERLW12 ER32 T347A, F367Y, R436R, L489M, L504P, L541M, M396R, S456S, L486S NA 
ERLW20 ? E339V, M396R, M337L, S456S, G521G, L525L EST (10^-7) 
ERLW7 24_5 P406H, K416I EST 
ER8GFP15 E380D E380D, R335R EST, 10^-5 GFP 
ER8GFP10 E380D E380D EST, 10^-5 GFP 
ERL19 12_8 N348S, G442R, L354L, K416Q, T431I EST, 10-5 GFP 
ER98LW10x ? V376D NA 
ERLW101 NCC13 L319M, T347A, F367Y, R436R, L489M, L504P, L541M,  E471G EST (10^-5 slight) 
ERLW14 12_8 N348S, G442R, N519S NA 
ER8GFP11 12_8 N348S, G442R, L453L EST, 10-5 GFP 




Figure 7.21 Ligand activated growth of ER8GFP11 and ERL19 variants. 
Engineered variants were tested with set of AMIs which was used for creation of 
library.      
 207 
in stead of a carboxylic acid as in AMI 23 or 24. On the other hand, AMI 81 which has 
incorporated tetrahydrotetramethylnaphatalenyl moiety in AMI core differs substantially 
from AMIs that activate ERα.  
Responsible for achieving novel functions are mutations of 12_8 variant which 
was used as template for creating next generation variants ER8GFP11 and ERL19. 
Variant 12_8, which was obtained in the first ERα library, was not tested for activation 
with AMI 81 and 73 previously. Sequencing results have shown that variant ER8GFP11 
has the same mutations as the 12_8 variant with an additional silent mutation at L453. 
However, variant ERL19 is a second generation of the 12_8 variant with two additional 
mutations, K416Q and T431I (Figure 7.22).  
Based on activation profiles of both variants, mutations of 12_8 (ER8GFP11) 
variant seems to be implicated in novel function of these variants. Thus, previous 
mutagenesis studies have shown that residue N348 stabilizing the ligand bound 
conformation of LBD by forming hydrogen bond with Y537 [18, 19]. However, residue 
G442 which is localized in helix eight is not close position to ligand binding pocket [19]. 
It has been shown that this residue takes place in contact with helix 1 and it is responsible 
for altering helix-helix interactions. Other mutagenesis studies have shown mutation 
G442V increased sensitivity to testosterone [20]. These previous studies indicate that 
obtained mutations perhaps stabilizing interactions in the ligand binding domain.  
The additional mutations K416Q and T431I which are present in the ERL19 
variant seem not to be essential for activation. This variant displays similar activation 







Figure 7.22 Crystal structure of ERα. Residues of variants 
ER8GFP11 and ERL19 are selected at crystal structure of ERα 
(shown in red), pdb: 1ERE. 
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The role of these residues for ligand binding have not been established and more 
mutagenesis studies need to be done to understand their role. 
 
7.7 Summary 
  The analysis of presented evolved ERα variants provided new insights into the 
molecular basis of ERα ligand specificity. Obtained variants have shown novel function 
toward activation by AMIs. Besides the novel functions, which were presented in the 
case of ERL19 and ER8GFP11 variants, enhanced activation was also achieved as shown 
in E380D variant. This variant was not only able to enhance activation with AMI 23 and 
24, which bind ERα, but also enhance fluorescence levels of AMIs in yeast as well as 
mammalian cells.  These results demonstrate that directed evolution of nuclear receptors 
may be beneficial towards creating novel variants with abilities to activate various ligand. 
Unfortunately, we were not able to engineer an orthogonal estrogen receptor which was 
activated by AMI but that lost affinity to 17β-estradiol. However, variants with decreased 
affinity to its natural ligand were obtained. They can be used for further engineering to 
create an orthogonal receptor-ligand pair. 
 In total, this insight can be applied toward engineering estrogen receptors using a 
random mutagenesis approach as well as by rational mutagenesis to enhance activation 




7.8 Materials and Methods 
Ligands 
 17-β estradiol (MW= 272.4 g/mol) was purchased from MP Biomedicals (Aurora, 
OH). The library of AMIs was synthesized by Dr. Anthony Baldridge. Method of 
synthesize was described previously in Chapter 2. 10 mM stocks of all ligands were made 
with 80 % ethanol: 20 % dimethyl sulfoxide (DMSO) and stored at 4 °C. 
 
Plasmid constructions 
 The pGBDERαLBD , and pGBDERαbackground plasmid were constructed 
previously. Also coactivators plasmids pGAD10BALXXLLSRC-1, pGAD10BASRC-1, 
pGAD10BALXXLLACTR and pGAD10BAACTR were cloned before.  
The created variant E380D was cloned into mammalian expression plasmid pCMX.  
 
Error – Prone PCR 
 The ERαLBD was amplified using pGBDERαLBD as the template DNA for error 
– prone PCR random mutagenesis using 0.5 µM of each ERPCR1For 5’ GGT CAA AGA 
CAG TTG ACT GTA TCG C 3’ and ERPCR8Rev 5’ GCC TCC CCC GTG ATG TAA 
ATA CT 3’ primers (Operon). In addition to primers PCR solution consist contained 500 
µM dNPTs, 7 nM MgCl2, 250 ng of template DNA, 1x Taq buffer, and Taq polymerase 
(Promega Bio-Tek)  with varied concentrations of MnCl2 or Mutazyme polymerase 
(Stratagene). The PCR program was run with following steps 95 °C for 1 minute, 95 °C 
for 30 seconds, 55 °C for 30 seconds, 72 °C for 1 minute, which were repeated 20 times 
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and followed by 72 °C for 4 minutes. The created cassettes were purified using the 
QIAprep® Spin Miniprep Kit (Qiagen). To create second and third generation of the 
variants, previous parents’ variants were used as template for amplification error –prone 
PCR.  
 
Yeast Transformation – Libraries Creation 
 Each ERα Library was created using 10 μg of the full insert cassette and 0.3 μg of 
the yeast expression background plasmids which were transformed into PJ69-A strain by 
using TRAFCO yeast transformation protocol. Transformation mix was plated on non-
selective (SC-LW) and selective (SC-ALW) agar plates. Selective plates contained 10 
µM of selected AMIs. Plates were incubated at 30 °C by 3-4 days. Based on the number 
of colonies on non-selective plates library size and transformation efficiency was 
calculated.  
 
Liquid Quantitation Assays 
 Obtained variants were rescue for pGBD plasmid which carried mutated ERα 
gene and sent for sequencing (Operon). Sequenced transformants were re-transformed 
into PJ69-A yeast strain and selected for further testing using liquid quantitation assay in 
chemical complementation. Transformants were incubated in non-selective media at 30 
°C overnight and shaken at 300 rpm. Variants after removing media and washing in 
distillated water were resuspended in selective media (SC-ALW) with concentration 
range of various AMIs in 96-well plates. Plates were incubated at 30 °C by 48 hours and 
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shaken at 170 rpm. Ligand activated growth was tested by taking reading of optical 
density at 630 nm of wavelength after 0, 24 and 48 hours of incubation.  
 
Fluorescence Microscopy 
 The PJ69-4A strain expressing ERα was incubated in selective media SC-ALW 
with AMIs, at 30 °C, shaking at 300 rpm. After incubation yeast were pelleted by 
centrifuging and resuspended in distill sterile water. Cells were again centrifuged and 
resuspended in water. Next the cell were displayed under fluorescent microscope and 
analyzed for green fluorescence. 
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EVALUATION OF AMI FOR LXRΒ IN MAMMALIAN CELLS 
 
 In Chapter 3, it was shown that the discrepancy between the activation profile of 
ERα in yeast and mammalian cells. These results indicated that NR activation tested 
using mammalian assay can provide more information than chemical complementation. 
Thus, LXRβ was subjected to test its activation profile with library of AMIs in 
mammalian cells. The HEK298T cells were co-transfected with the mammalian 
expression vector pCMXGLXRβLBD expressing Gal4DBD:LXRβLBD fusion protein 
and vector carrying Gal4 response element under luciferase promoter. Cells were 
incubated in media with library of 60 compounds of AMIs. As a control, cells were 
incubated with known LXRβ ligand, T090. As shown in Figure 6.12 LXRβ was not 
activated by any AMI compounds. These results indicated that AMI core is not suitable 














































Figure A.1. Activation profile of 60 AMIs in LXRβ. Part I. LXRβ (GBD: 
LXRβLBD) was transfected into HEK298T cells with p17*4TATALuc 
plasmid, a luciferase reporter gene under the control of Gal4 response 
elements and were incubated with 10 µM of ligand. Structures of all above 
ligands are included in appendix. 
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Figure A.1. Activation profile of 60 AMIs in LXRβ. Part II. LXRβ (GBD: 
LXRβLBD) was transfected into HEK298T cells with p17*4TATALuc 
plasmid, a luciferase reporter gene under the control of Gal4 response 
elements and were incubated with 10 µM of ligand. Structures of all above 




Figure A.1 Activation profile of 60 AMIs in LXRβ. Part III. LXRβ (GBD: 
LXRβLBD) was transfected into HEK298T cells with p17*4TATALuc 
plasmid, a luciferase reporter gene under the control of Gal4 response 
elements and were incubated with 10 µM of ligand. Structures of all above 




LIBRARY OF AMI DERIVATIVES 
 
 











#  R1  R2  R3  R4  #  R1  R2  R3  R4  
1  4-Me  H  Me  Me  89  3,5-Me  
4-OH  
H  Me  Me  
2  3-OMe  H  Me  Me  90  3-F  H  Me  Me  
3  3-OH  H  Me  Me  91  3-OH  H  C3CO2H  Me  
4  2,3-OMe  H  Me  Me  92  4-OC12H25  H  Me  Me  
5  4-NO2  H  Me  Me  93  4-OMe  H  Me  Me  
6  2,5-OMe  H  Me  Me  94  2-OMe  H  Me  Me  
7  3,5-t-Bu  
4-OH  
H  Me  Me  95  4-OMe  H  n-Pr  Me  
8  4-CO2H  H  Me  Me  96  4-Cl  H  n-Pr  Me  
9  4-N(Me)2  H  Me  Me  97  4-Br  H  Me  Me  
10  2-F  H  Me  Me  98  2-OMe  H  n-Pr  Me  
11  4-OBz  H  Me  Me  99  2-Br  H  Me  Me  
12  2,4,5-OMe  H  Me  Me  100  4-PhC8H17  H  Me  Me  
13  2-pyridyl-4-OH  H  Me  Me  101  4-Br  H  n-Pr  Me  
14  4-OH  H  Me  Me  102  2-Br  H  n-Pr  Me  
15  2-Me  H  Me  Me  103  3-F  H  n-Pr  Me  
16  4-CN  H  Me  Me  104  3-Cl  H  Me  Me  
17  4-N(Et)2  H  Me  Me  105  3-OMe  H  n-Pr  Me  
18  4-OH  H  n-Pr  Me  106  Benzyl  H  n-Pr  Me  
19  4-OH  H  n-Pn  Me  107  3-OH  H  C3CO2H  Me  
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20  4-OH  H  n-Bu  Me  108  Benzyl  H  C3CO2H  Me  
21  4-Me  H  n-Pr  Me  109  4-PhC5H11  H  Me  Me  
22  4-N(Me)2  H  n-Pr  Me  110  4-i-Pr  H  Me  Me  
23  4-OH  H  C3CO2H  Me  111  3,4-Me  H  Me  Me  
24  4-OH  H  C5CO2H  Me  112  2-OH  
4-N(Et)2  
H  n-Pn  Me  
25  1-naphthyl  H  Me  Me  113  2-OH  
4-N(Et)2  
H  n-heptyl  Me  
26  4-Et  H  Me  Me  114  2-OH  
4-N(Et)2  
H  n-Pr  Me  
27  3-Me  H  Me  Me  115  4-N(Et)2  H  n-hexyl  Me  
28  2,4-Me  H  Me  Me  116  2-OH  
4-N(Et)2  
H  n-hexyl  Me  
29  2-quinoline  H  Me  Me  117  2-OH  H  n-Pr  Me  
30  2,5-Me  H  Me  Me  118  3-Cl  H  n-Pr  Me  
31  1-naphthyl  H  Et  Me  119  2-OH  
4-N(Et)2  
H  Dodecyl  Me  
32  4-i-Pr  H  n-Pr  Me  120  2-OH  
4-N(Et)2  
H  Octyl  Me  
33  4-N(Me)2  H  n-Bu  Me  121  4-i-Bu  H  C3CO2H  Me  
34  2-CF3  H  Me  Me  122  4-i-Bu  H  n-heptyl  Me  
35  2-naphthyl  H  Me  Me  123  3,4-Me  H  C3CO2H  Me  
36  4-N(Et)2  H  i-Pr  Me  124  3-pyridyl  H  Me  Me  
37  4-OH  H  EtOH  Me  125  3-Br  H  n-Pr  Me  
38  4-OH  H  CH2(CF2)7  
CF3  
Me  126  2,4-Cl  H  Me  Me  
39  4-Et  H  n-Pr  Me  127  2-OH  H  Me  Me  
40  2-Et  H  Me  Me  128  3-Br  H  Me  Me  
41  2-Me  H  n-Pr  Me  129  4-PhC3H7  H  Me  Me  
42  2-Me  H  CH2CF3  Me  130  3,5-t-Bu  
4-OH  
H  n-Pr  Me  
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43  4-OH  H  PrOH  Me  131  3,5-t-Bu  
4-OH  
H  n-Pn  Me  
44  2-Et  H  n-Pr  Me  132  3,5-t-Bu  
4-OH  
H  n-hexyl  Me  
45  3-NO2  H  Me  Me  133  4-OMe  H  EtOH  Me  
46  4-N(Et)2  H  n-Pr  Me  134  3,4-OMe  H  n-Pr  Me  
47  2,6-Me  H  Me  Me  135  2-OH  
3-OEt  
H  2-phenol  Me  
48  4-i-Pr  H  Me  Me  136  4-OH  H  C2N(Me)2  Me  
49  4-t-Bu  H  Me  Me  137  3-OH  H  C2N(Me)2  Me  
50  3-indole  H  Me  Me  138  2-OH  Me  Me  Me  
51  2-F  H  n-Pr  Me  139  4-N(Et)2  H  C2-sym  Me  
52  4-N(Me)2  H  i-Pr  Me  140  Benzyl  H  C2N(Me)2  Me  
53  4-tetralin  H  Me  Me  141  3,5-t-Bu  
4-OH  
H  EtOH  Me  
54  2-Me  H  Et  Me  142  2-OH  
4-OMe  
H  n-Pr  Me  
55  4-N(Et)2  H  n-Pn  Me  143  2,4-Cl  H  n-Pr  Me  
56  Benzyl  H  Me  Me  144  4-N(Et)2  H  C4-sym  Me  
57  2-OH  
3-OEt  
H  Me  Me  145  2-OH  
4-OMe  
H  Me  Me  
58  4-F  H  Me  Me  146  Piperonal  H  Me  Me  
59  2-OH  
4-N(Et)2  
H  Me  Me  147  2-CF3  H  n-Pr  Me  
60  2-imidazole  H  Me  Me  148  4-OH  H  Allyl  Me  
61  2-Et  H  Et  Me  149  2,5-OMe  H  n-Pr  Me  
62  3-Me  H  n-Pr  Me  150  4-N(Me)2  H  PrOH  Me  
63  2-Me  H  n-Bu  Me  151  3-OH  
4-Br  
H  Me  Me  
64  2-Me  H  n-Pn  Me  152  4-OH  H  2-heptyl  Me  
65  2-Me  H  i-Pr  Me  153  4-Ph  H  Me  Me  
66  3-OMe  
4-OH  
H  C3CO2H  Me  154  4-OMe  H  Allyl  Me  
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67  4-Me  H  Et  Me  155  2-OH  
4-OMe  
H  PrOH  Me  
68  2,3-OMe  H  C3CO2H  Me  156  4-N(Me)2  H  2-heptyl  Me  
69  4-N(Et)2  H  C3CO2H  Me  157  4-OC4H9  H  Me  Me  
70  4-Cl  H  Me  Me  158  4-N(Me)2  H  C3N(Me)2  Me  
71  3-CF3  H  n-Pr  Me  159  4-N(Me)2  H  C2CN  Me  
72  4-CF3  H  Me  Me  160  2-OH  
4-N(Et)2  
H  C2-sym  Me  
73  4-OH  H  C3N(Me)2  Me  161  4-Me  H  C2H4CN  Me  
74  3-CF3  H  Me  Me  162  2-Indole  H  n-Pn  Me  
75  2,4-OH  H  C3CO2H  Me  163  3-OH  H  2-heptyl  Me  
76  3,4-OH  H  C3CO2H  Me  164  3-OH  H  3-Pn  Me  
77  2-Cl  H  Me  Me  165  2-Indole  H  C3N(Me)2  Me  
78  2-Cl  H  n-Pr  Me  166  4-N(Me)2  H  EtOH  Me  
79  4-CF3  H  n-Pr  Me  167  4-N(Et)2  H  C6-sym  Me  
80  3,5-Me  H  Me  Me  168  2-Indole  H  n-Pr  Me  
81  4-tetralin  H  C3CO2H  Me  169  3-OH  H  2-heptyl  Me  
82  Benzyl  H  C3CO2H  Me  170  4-CN  H  PrOH  Me  
83  2-OH  
4-N(Et)2  
H  C3CO2H  Me  171  4-OBu  H  n-Pn  Me  
84  4-N(Me)2  H  C3CO2H  Me  172  4-OH  H  3-Pn  Me  
85  4-OC6H13  H  Me  Me  173  4-OH  H  CH2CF3  Me  
86  2,6-Me  
4-OH  
H  Me  Me  174  4-N(Me)2  H  Allyl  Me  
87  3,5-t-Bu  
4-OH  
H  Benzyl  Me  175  4-OH  H  C2H4CN  Me  
88  4-OH  H  Benzyl  Me  
